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ABSTRACT

Tetraspanin CD151 is highly expressed in endothelial cells and regulates
pathological angiogenesis. However, the mechanism by which CD151 promotes vascular
morphogenesis and whether CD151 engages other vascular functions are unclear. We
observed that CD151 is required for the maintenance of endothelial capillary-like
structures formed in vitro and the integrity of lung endothelial cell-cell contacts in vivo.
As a master regulator of endothelial cell-matrix and cell-cell adhesions, CD151 is needed
for the optimal functions of various cell adhesion proteins such as integrin, cadherin, and
CD44. The loss of CD151 elevates the cellular intrinsic contraction by upregulating
RhoA signaling and downregulating of Rac1 activity. CD151 balances RhoA and Rac1
activities and stabilizes the membrane-cytoskeleton connection. In the absence of CD151
expression, the inhibition of RhoA signaling axis enhances the diminished cell-cell
adhesiveness and stabilizes vascular structures. In addition, CD151-dependent vascular
stabilization involves cAMP signaling and might thus regulate RhoA and Rac1. Together,
CD151 reinforces vascular stability by promoting endothelial cell-matrix and cell-cell
adhesions to counterbalance the destabilization derived from RhoA signaling-mediated
cytoskeletal tension.
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CHAPTER 1. INTRODUCTION

1.1 Vascular Morphogenesis and Vascular Stability

1.1.1 An Introduction to Vascular Morphogenesis
An essential requirement for adequate organ performance is the formation of
blood vessels that transport nutrients and maintain hemostasis. Vasculogenesis and
angiogenesis are the two in vivo morphogenic processes of blood vessel formation.
Vasculogenesis refers to the de novo development of capillaries from individual
endothelial precursors, while angiogenesis refers to new blood vessel formation from
preexisting vessels.1 Vascular morphogenesis is the process in which endothelial cells
assemble into capillary structures and is required for both vasculogenesis and
angiogenesis.1

1.1.2 Cell-matrix Adhesion, Cell-cell Adhesion, and Cytoskeletal Organization Are
Important for Vascular Morphogenesis and Vascular Stability
During vascular morphogenesis, endothelial cells assemble into inter-connected
multicellular structure by the linkage between cells through cell-cell adhesion and
attachment on basement membrane through cell-matrix adhesion.2,3 The interactions
between cell and matrix and among cells are critical for endothelium to resist the constant
tension from the endothelial actin cytoskeleton and the shear force from blood flow.2,3
Endothelial cell-matrix adhesion is mediated by a number of specific adhesive
proteins, of which integrins are of main importance.4 Integrins are a group of
heterodimeric cell surface receptors composed of non-covalently associated α and β
subunits and bind with their extracellular matrix (ECM) ligands to mediate cell-matrix
adhesion.5,6 Vessels contain various integrins such as fibronectin-binding integrin α5β1,
and laminin-binding integrins α3β1, α6β1 and α6β4.4 The integrin-matrix engagement is
not only responsible for endothelial cell adhesion to matrix environment and but also
involved in regulation of vascular functions.4 For example, integrin α5β1 is of particular
importance in vascular development.7 In addition, other endothelial cell-matrix adhesion
molecules such as CD44 are also important for angiogenesis.8,9
Endothelial cell-cell adhesion is also crucial for blood vessel formation as the
vessel wall is formed largely or partially by the endothelial cell layer in which adjacent
endothelial cells attach to each other through cell-cell contacts to maintain hemostasis.2,3
1

VE-cadherin is an endothelium-specific cell-cell adhesion molecule that physically and
functionally associates with α-, β-, and γ-catenin, and p120ctn to form adherens junctions
(AJ).10-12 VE-cadherin is essential for the morphogenesis of vessel-like structure in
vitro,12-14 and the ablation of VE-cadherin or function-blocking antibodies effectively
reduce neovascularization in animal.14,15 In addition to VE-cadherin, endothelial cells
express other cell-cell adhesion proteins such as occludin, claudins and junctional
adhesion molecule-1 (JAM-1) in tight junctions (TJ), and platelet endothelial cell
adhesion molecule (PECAM), vascular cell adhesion molecule (VCAM) and intercellular
adhesion molecule-1 (ICAM-1) and -2 which are not specifically confined to AJ and
TJ.11,16 Among these molecules, PECAM-1 and ICAM-2 have also been implicated in the
regulation of angiogenesis.11,16
Cytoskeletal organization is also important in vascular morphogenesis and
vascular stability. Rho family GTPases control various cytoskeleton reorganization events
such as Rac1- and Cdc42-dependent protrusions and RhoA-mediated cell
contraction/retraction.17 It has been established that Rac1, Cdc42, and RhoA are
important for the vessel structure formation.1,18-21 For example, Rac1 and Cdc42
activations are needed for angiogenesis,22,23 and are specifically required for the
formation of capillary lumen in 3D extracellular matrices.1,18,24 In contrast, the activation
of RhoA destabilizes angiogenic vessels, and is required for vessel regression, whereas
either the inhibitors specific to RhoA signaling or the signaling that suppresses RhoA
activation, such as Src family kinases and ERK-MAPK signaling, promote vessel
stability.19-21
Rho family GTPases and cadherin-mediated cell-cell adhesion are mutually
regulated.25-28 For example, RhoA-dependent cytoskeletal tension promotes the
disassembly of cell-cell adhesion via myosin II-mediated actin reorganization.29
Expression of constitutively activated RhoA disrupts adherens junctions, and inhibitors of
RhoA signaling reinforce cell-cell adhesions.26 On the other hand, the adherens junctional
complex consisting of cadherin, β-catenin, and p120ctn inhibits RhoA signaling through
recruiting p190RhoGAP into the junctional complex.30 Hence, RhoA likely balances
cytoskeletal tension and cell-cell adhesion.

1.2 Tetraspanins and Vascular Functions
Tetraspanins are a group of type III transmembrane proteins which span cell
membrane 4 times.31 Tetraspanins contain four conserved hydrophobic transmembrane
domains (TM1-TM4), intracellular N- and C-terminal domains, and small (EC1) and
large (EC2) extracellular domains.31-35 A schematic representation of tetraspanin domain
structure is shown in Figure 1-1. The EC2 domain of tetraspanins features several
2

Figure 1-1. Schematic representation of the structure of tetraspanins.
Tetraspanins consist of four transmembrane, intracellular N- and C-terminal domains, and
two extracellular (one shorter, EC1, and one longer, EC2) domains. The EC2 is featured
by the ‘CCG’ and ‘PXXCC’ motifs. Most of tetraspanins have glycosylation sites in EC2
as indicated as the squares, while CD9 is glycosylated in EC1. In each tetraspanin, there
are several cysteine residues proximal to the interface of the inner leaflet and cytosol,
which are the sites for palmitoylation and characteristic strong polar residues in the
transmembrane domains. Tetraspanins also contain a ‘YXXΦ’ endocytic sorting motif in
the C-terminal cytoplasmic domain. C, Cysteine; E, Glutamic acid; G, Glycine; P, Proline;
Q, Glutamine; N, Aspargine; S, Serine; Y, Tyrosine; X, any amino acid; Φ, Hydrophobic
amino acid.
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cysteine residues, glycosylation sites, and highly conserved “CCG” and “PXXCC” motifs,
while transmembrane domains contain palmitoylation sites. Tetraspanins interact with
each others and with other membrane bound proteins such as integrins31-35 and Ig
superfamily proteins36 through numerous protein associations to form
tetraspanin-containing multimolecular complexes in the membrane designated as
“tetraspanin web” or “tetraspanin enriched microdomains” (TEM).31,37,38 TEMs are
organized as the functional units for specific regulations of various cellular processes
such as cell adhesion, enzymatic activities, protein compartmentalization and membrane
presentation and etc on cell plasma membrane. 31,37,38 However, with the exception of
CD151-integrin α3β1 binding, most interactions of tetraspanins with other
transmembrane proteins are probably not based on the direct amino acid residue-amino
acid residue interactions at the EC regions because they are readily disrupted under the so
called “high stringency” detergent conditions used to lyse cells (e.g., 1% Triton X-100).
As the organizers in TEM, tetraspanins regulate vital cellular processes such as
adhesion, spreading, migration, and fusion and these processes-dependent signaling
pathways (Figure 1-2) as observed in various in vitro and in vivo systems.39-43 In addition,
recent studies reveal that tetraspanins actively traffic between plasma membrane and
intracellular vesicular compartments, and their trafficking is accompanied by the
vesicular release and regulates the trafficking of other membrane proteins such as
integrins.44,45 Another emerging theme is that tetraspanins appear to regulate pericellular
proteolysis near the plasma membrane, leading to altered cell movement and
adhesiveness.46-49 Thus, tetraspanins have been defined as molecular “facilitators” or
“organizers” at the plasma membrane of both intracellular vesicles and extracellular
microenvironment.
Many tetraspanins are expressed in vascular system. For example, CD9, CD63,
and CD151 are highly expressed in endothelial cells, and others such as TSSC6 are
expressed in hematopoietic cells. Because cell adhesion proteins regulate vascular events
such as neointimal formation, angiogenesis, and thrombosis and tetraspanins play key
roles in adhesion and migration, tetraspanins likely modulate important
pathophysiological process of the vascular system. Indeed, by differentially associating
with integrins and other membrane molecules, tetraspanins such as CD9, CD151, CD63
and TSSC6 take part in diverse vascular events including smooth muscle cell (SMC)
proliferation and migration, endothelial cell adhesion, platelet aggregation and
thrombosis, angiogenesis, and haemostasis.50 The biology of vascular tetraspanins and
their regulatory roles in the pathophysiological processes related to cardiovascular system
become better understood recently.50 However, the expression and function of most
newly identified tetraspanins in the vascular system remain to be elucidated.

4

Figure 1-2. Schematic drawing showing cellular functions of tetraspanins.
Tetraspanins associate with integrins, Ig superfamily proteins, and other transmembrane
proteins to form microdomains on membrane designated as ‘tetraspanin web’ or
‘tetraspanin enriched microdomians’ (TEM) and serve as organizers at the plasma
membrane. Tetraspanins are also enriched in the intracellular vesicles, and trafficking of
tetraspanins between various cellular compartments tightly regulates exocytosis and
trafficking of their associated partners. Tetraspanins, in conjunction with other membrane
proteins, regulate cell-matrix adhesion, cell-cell adhesion, cell migration, and
intracellular signaling events.
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1.3 Tetraspanin CD151

1.3.1 Chromosomal Locus of CD151 Gene
CD151, originally identified as platelet-endothelial cell tetra-span antigen 3
(PETA-3), is a member of tetraspanin family.51 Human CD151 gene is located on
chromosome 11p15.5.52 The gene spans ~ 5 kb of genomic DNA and consists of 8
exons.52 Mouse CD151 gene spans ~ 4 kb on chromosome 7, and comprises 7 exons.53,54
The exon-intron organization of human CD151 gene is summarized in Figure 1-3A.52,54

1.3.2 Gene Expression and Regulation of CD151
Human CD151 gene produces two transcripts by alternative splicing and forms ~
1.6 kb mRNA molecules. The shorter transcript variant PETA-3 has a 62-bp deleted
region in the 5’-untranslated region compared with the longer one.55 Mouse CD151
mRNA is approximately 1.8 kb in length, and has three alternative splicing variants with
different 5’-untranslated region regions.53,54 Both human and mouse CD151 mRNAs
contain a single open reading frame encoding 253 amino acid residues with 93% identity
to each other.53
A recent study demonstrated that the transcription factor SP1 controls CD151
expression in human liver cancer cells partially through establishing a local open
chromatin configuration in CD151 promoter.56 CD151 expression can also be induced by
human T-cell leukemia virus type 1 (HTLV-1) and transactivated by Tax in platelets.57 In
addition, CD151 expression can be upregulated after overexpression of its associated
integrin α3β1, α6β4 or α7β1 in cultured cells such as K562 cells and PA-JEB
keratinocytes through mechanisms that remain unclear.58,59

1.3.3 Protein Structure of CD151
CD151 protein consists of 253 amino acid residues with a molecular weight of
~ 28 kDa.51 As a member of tetraspanin family, CD151 has a typical tetraspanin domain
structure, containing four transmembrane domains (TM1-TM4), a short and long
extracellular domains (EC1 and EC2), and N- and C-terminal cytoplasmic domains
(Figure 1-3B).51-53 In human CD151, each of the four transmembarne domains is formed
by a hydrophobic segment containing ≥ 22 amino acid residues.51 The hydrophilic EC1
(between TM1 and TM2) and EC2 (between TM3 and TM4) domains are composed of
18 (positions 40-57) and 109 (positions 113-221) residues, respectively, while the
6

Figure 1-3. Schematic drawing of genomic organization and protein domain
structure of human CD151.
(A) Intron-exon organization of CD151. CD151 gene contains 8 exons, 75-700bp in size,
with 5’- and 3’-noncoding regions ( ) and coding region ( ). (B) Protein domain
structure of CD151. The protein has a typical tetraspanin domain structure (Figure 1-1)
consisting of N- and C-terminus, TM1-TM4, EC2 and EC2 domains with featured
residues. The corresponding exon coding regions of the domains are indicated.
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intracellular N- and C-termini consist of 16 (positions 1-16) and 7 (positions 247-253)
hydrophilic residues, respectively.51,60 The EC2 contains six cysteine residues, four of
which are located in “CCG” and “PDSCC” motifs corresponding to residues 155-157 and
181-185, respectively.51 Both cysteine-containing motifs are critical in determining
appropriate folding of the EC2 domain of CD151.61 A potential glycosylation site,
located at asparagine residue 159, appears not to be required for interactions of CD151
with other tetraspanins but rather contributes to the modulatory activities of CD151.62 In
addition, like other tetraspanins, CD151 contains a set of palmitoylation sites at the
cysteine residues, including positions 11, 15, 79, 80, 241 and 242, proximal to TM1,
TM3 or TM4.63,64 The palmitoylation of CD151 occurs in Golgi or post-Golgi
compartments,64 and is specifically mediated by DHHC2, a member of the “DHHC”
(Asp-His-His-Cys) family of protein acyltransferases (PATs).65 It has been shown that
the palmitoylation protects CD151 from lysosomal degradation and is important in
establishing the interactions of CD151 with integrins and other tetraspanins in TEM and
modulating integrin-dependent functions.63-66 Notably, because of the glycosylation and
palmitoylation of the protein, the appearance of CD151 on SDS-PAGE is a diffuse band
with a range of 27-37 kDa in molecular weight.

1.3.4 Tissue Localization of CD151
CD151 is ubiquitously expressed. Northern blotting analysis showed that CD151
mRNA is present in all tissues, with the exception of brain, in both human and mouse.51,53
Immunohistochemistry analysis confirmed the broad distribution of CD151 protein in
human tissues.67 With respect to cell types, CD151 is expressed by endothelial cells,
epithelial cells, fibroblasts, platelets, megakaryocytes, erythrocytes, Schwann cells,
dendritic cells and by all types of muscle cells.67,68 The expression of CD151 in
endothelial cells is particularly high and throughout vasculature of all human tissues,67
suggesting it plays important roles in vascular functions.

1.3.5 Association of CD151 with Integrins and Other Tetraspanins
Previous studies have well established that CD151 interacts with laminin-binding
integrins α3β1, α6β1, α6β4, and α7β1 and other tetraspanins such as CD9, CD81 and
CD63.59-61,63,64,69-73 CD151 associates with at least one of the laminin-binding integrins in
epithelial and endothelial cells and myocytes, and the association is independent of the
ligand occupancy of these integrins. Whereas it may associate other integrins in
fibroblasts or stromal cells which have no laminin-binding integrins present.71,74
CD151 selectively forms highly stable and stoichiometric associations with
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integrin α3β1, which shows resistance to the extraction by high stringency detergent (e.g.,
1% Triton X-100).59,69 The interaction of CD151 with integrin α3β1 is mediated directly
by physical contact between EC2 region of CD151 and the membrane-proximal region of
integrin α3 ectodomain.59,61 The mutagenesis analysis suggests that the region containing
residues 150-212 in EC2 of CD151 confers the specific and strong interaction of CD151
with integrin α3β1, whereas EC1 and TMs are responsible for surface localization of
CD151.61 The sub-region of residues 185-217 in EC2 is of particular importance in
CD151-integrin α3β1 association.60,61 Results from epitope mapping with CD151 mAbs
have confirmed that two consecutive segments within the above specific 185-217
sub-region, the Leu191-containing 185-192 peptide and the Gln194-containing QRD
peptide, comprise an interface between CD151 and integrin α3β1 and mediate the stable
association between the two proteins, although other residues such as Gly176/Gly177 and
the cysteine residues in “CCG” and “PDSCC” motifs are also important for
CD151/integrin α3β1 interaction.61,75 In contrast to the interactions of CD151 with other
integrins and tetraspanins, the one between CD151 and integrin α3β1 exhibits a unique
feature, i.e. the assembly of integrin α3β1-CD151 complex occurs before their secretion
onto plasma membrane, likely during early stage of the biosynthesis of the integrin in
ER.61 The interactions between CD151 and integrin α6β1 and α6β4 are weaker so that it
is not resistant to harsh detergents such as 1% Nonidet P-40 (NP-40) but still fairly
stable,58,71,73,76 while the association of integrin α7β1 with CD151 is equally strong
compared with that of α3β1.71 CD151 may also use EC2 to interact with the α subunit in
integrins α6β1, α6β4, and α7β1.58,59,71,76 However, the structural elements in CD151
responsible for associations with these integrins need to be further elucidated.
CD151 also interacts with other tetraspanins such as CD9, CD81, and CD63 and
thus participates in the formation of TEM.61,64,77,78 These interactions appear to be
indirect and less stable.61,78 Mutagenesis analysis suggests the EC2 region is not required
for the interactions of CD151 with CD9, CD81, and CD63, while the palmitoylation of
CD151 is necessary for these interactions.61,64,66 In addition to the heterotypic interaction
with other tetraspanins, CD151, like other tetraspanins, also forms homodimers which
appear to be more stoichiometric and prevalent than the heterodimers such as
CD9/CD151 and CD81/CD151.61,78 These homodimers are believed to be assembled
from newly synthesized proteins in Golgi and subsequently transported to the cell surface
where they might serve as so called “building blocks” for establishment of “tetraspanin
web” with other proteins.61,78 The cysteine residues at the palmitoylation sites and in the
“CCG” motif of CD151 play pivotal roles in the assembly of the dimmers.61,78
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1.3.6 Functions of CD151

1.3.6.1 The Roles of CD151 in Integrin-dependent Functions
CD151 is believed to be an important adaptor which facilitate connection of
integrins to the tetraspanin web and thus modulate integrin functions.59 CD151 is
constantly involved in integrin α3β1-dependent processes due to their firm association.
First, CD151 regulates α3β1-dependent cell motility in a variety of cells.59,79,80 Second,
CD151 colocalizes with integrin α3β1 in cell-matrix adhesion structures and substantially
modulates α3β1-dependent cell adhesion on not only laminin 5 but also laminin 10, the
two ligands of α3β1, likely through potentiating the ligand-binding abilities of the
integrin by stabilizing its active conformation.79,81-83 Moreover, integrin α3β1-CD151
complex acts as a functional unit and makes a strong contribution to cell morphogenesis
and neurite outgrowth.82,84 Mechanistically, CD151 appears to mediate
compartmentalization of α3β1 into TEM44,63,79 and associate with and/or modulate major
signaling molecules such as the phosphatidylinositol signaling effectors
phosphatidylinositol 3 kinase (PI3K)63 and phosphatidylinositol 4 kinase (PI4K),59 protein
kinase C (PKC),85,86 and receptor tyrosine kinase cMet/HGF receptor.87 CD151 thus
selectively regulates these pathways and trigger the downstream signaling events such as
protein phosphorylation for Src, focal adhesion kinase (FAK), p130Cas, paxillin, and α3
integrin, through which CD151 contributes to α3β1-dependent cell proliferation,
migration, adhesion, and morphogenesis.59,63,79,82,85-90
Integrin α6β4 is another cellular receptor of laminin 5.58 Similarly, CD151
contributes to integrin α6β4-dependent processes such as cellular morphogenesis and the
spatial organization of hemidesmosomes possibly by enforcing integrin α6β4 connection
to the tetraspanin web.58,64 CD151 has also been shown to selectively promote integrin
α6β1-mediated cell spreading and adhesion strengthening on laminin 1 (an integrin α6β1
ligand) and cellular morphogenesis on Matrigel.76,91 The short C-terminal cytoplasmic
domain of CD151 is believed to be of particular importance for modulating "outside-in"
functions of integrin α6β1 upon ligand binding.76,91 Although the functional relationship
between CD151 and inegrin α7β1, a receptor of laminin 2, is still unclear, it is predicted
that CD151 may participate in integrin α7β1-dependent functions such as Schwann cell
myelination and muscle development.92-95
The concept of tetraspanins as adaptors mediating compartmentalization of
integrins into TEM and organizing the interactions of integrins with other proteins within
TEM helps explain how tetraspanins facilitate integrin functions. How does CD151
mediate compartmentalization of integrins? On the one hand, CD151 specifically
modulates the post-translational modifications of its associated integrins such as the
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glycosylation of integrin α3β1 on N-linked sites of the α3 subunit during the biosynthesis
of this integrin in ER and Golgi.62 Such modifications likely affect the stability, folding,
and membrane presentation of this integrin.62 On the other hand, CD151 directly regulates
integrin trafficking to and from the plasma membrane and between intracellular
compartments. CD151 and its associated integrins undergo endocytosis and accumulate in
the same intracellular vesicular compartments, suggesting a key role for CD151 in
regulating the trafficking of these integrins.44,73 Indeed, during cell migration on laminin 1
or 5, CD151 promotes the endocytosis and/or vesicular trafficking of integrins α3β1,
α5β1, and α6β1.44,79 It has been demonstrated that a YXXΦ type of endocytosis/sorting
motif, the YRSL sequence, is located at the C-terminal cytoplasmic domain of CD151.44
The YXXΦ motif-mediated internalization of CD151 plays critical roles in modulating
integrin trafficking and thereby contributes to integrin-dependent cell migration.44

1.3.6.2 CD151 Is a Tumor Metastasis Promoter
Increased CD151 expression has been shown to be associated with a poor
prognosis for patients with lung, liver, prostate cancer or other cancer types.96-100 Given
the ability of CD151 to promote cell migration, earlier studies have identified CD151 as a
positive regulator for tumor metastasis.98,101-104 Tumor metastasis is the process by which
tumor cells migrate from primary tumor to distal organs and represents advanced
malignancy.105,106 The metastasis cascade contains numerous sequential biological
processes which can be in general subdivided into the following steps: 1) cell dissociation
from primary tumor foci; 2) cell migration and invasion and angiogenesis; 3)
intravasation; 4) circulation transportation; 5) extravasation; 6) formation of metastatic
foci; and subsequent 7) tumor cell proliferation and angiogenesis.105-107 Among these
steps, CD151 specifically takes part in tumor cell migration and invasion, intravasation,
extravasation, and angiogenesis by altering cell motility, cell adhesion, proteolytic
activity of MMPs, and transforming growth factor β (TGFβ) signaling.
Cell motility is a key parameter that determines the behavior of malignant tumor
cells throughout the entire metastatic process. Integrin-dependent cell migration is
apparently crucial for tumor metastasis, and CD151 enhances integrin-dependent
migration and invasion of a wide variety of tumor cells in vitro.72,79,87,101,104,108-110 In vivo,
CD151 promotes tumor metastasis by enhancing tumor cell motility.101,102,104 CD151 was
shown to enhance tumor cell migration during their departure from primary tumor mass,
which leads to tumor cell invasion into surrounding connective tissue and
intravasation.101,102 A metastasis-blocking CD151 mAb (IA5) was found to immobilize
tumor cells by blocking intravasation and subsequently suppress metastasis in vivo.102
The regulatory role of CD151 in cell migration is apparently dependent on its association
with laminin-binding integrins.44,59,79,104 Mechanistically, migrating cells form protrusions
11

such as lamellipodia and filopodia containing motile structures which mediate the
detachment and re-attachment cycle for migration and induce small GTPases Rac- and
Cdc42- dependent reorganization of actin cytoskeleton.111 CD151 was found to 1) induce
Rac1 and Cdc42 signaling and actin cytoskeletal reorganization,74,85,112 2) colocalize with
integrin α3β1 at the leading edges of lamellipodia and filopodia,79,81 and 3) regulate
integrin α3β1-initiated signaling to FAK and PI4K, which are important regulators in cell
adhesion and cytoskeleton reorganization, respectively.59,82,112 Thus, to enhance cell
motility, CD151-integrin α3β1 complexes induces lamellipodia and filopodia formation
and directly modulates the dynamic adhesive structures at the edge of these cellular
extensions. However, other mechanisms by which CD151 regulates cell motility also
exist. For example, CD151 promotes cell migration by regulating intracellular trafficking
of integrins.44,79 It has been proposed that, during cell migration, the internalization of
CD151 result in the endocytosis of its associated TEM components such as integrin α3β1
when this integrin disengages from ECM.44 The ECM-disengaged integrins are
internalized from the trailing edge of migrating cells and likely recycled back to the
leading edge under CD151 escort to re-engage with ECM.44 In this regard, CD151
enhances the internalization and reutilization of integrins by facilitating their trafficking
and thus accelerates the detachment and re-attachment cycles to enhance cell migration.
Another aspect of tumor metastasis that CD151 may affect is cell adhesion, both
cell-matrix adhesion and cell-cell adhesion, within primary tumor and during metastasis.
Cell-matrix adhesion is believed to be the cell behavior crucial for tumor metastasis not
only because of the importance of cell adhesion in tumor cell motility, as discussed
above, but also because of the adhesion-dependent activation of various
metastasis-required signaling events such as MMPs production and protein
phosphorylation.46,49,59,63,86,113-115 It has been extensively discussed that the principal role
of CD151 is to stabilize cell-matrix interaction by associating with integrins α3β1 and
α6β4 at the basal cell surface.58,79,81-83 Thus, it is plausible that CD151-mediated
promotion of tumor metastasis is largely dependent on its ability to facilitate integrins to
establish adhesion of metastatic cells to ECM during not only tumor cell migration and
invasion but also in the subsequent formation of metastatic foci in distal organs. In
addition to cell-matrix adhesion, CD151 has also been shown to stabilize the homotypic
cell-cell adhesion of epithelial or tumor cells85,116,117 and heterotypic adhesion between
endothelial cells and leukocytes during leukocyte extravasation.118 A substantial
proportion of cell surface CD151 colocalizes with integrin α3β1 and cadherins at lateral
junctional sites in both epithelial and endothelial cells,73,85,108,116,117 suggesting a role of
CD151-integrin α3β1 complex in regulation of cadherin-based AJs. The establishment of
AJ involves cell polarization, fillipodia-based membrane extension and contact, cadherin
puncta formation and assembly of the junctional complex, and anchorage of the complex
to actin cytoskeleton through the linkers such as α-actinin and vinculin.119,120
Observations from epithelial and tumor cells suggest that CD151-integrin α3β1 complex
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is associated with AJ and essential for the filopodia-based adhesion zipper formation at
an initial stage and the anchorage of E-cadherin to cortical actin filaments at later stages
in a PKC- and Cdc42-dependent manner, without affecting AJ complex assembly.85,116,117
The downregulation of E-cadherin is the hallmark of eptithelial-mesenchymal transition
(EMT), which may lead to tumor metastasis under pathological conditions.121
CD151-dependent regulation of cell-cell adhesion in epithelial and tumor cells might
provide another potential mechanism by which CD151 facilitates tumor progression.
Moreover, CD151 in its associated TEM has a crucial role in ICAM-1 and
VCAM-1-mediated heterotypic intercellular adhesion between endothelial cells and
leukocytes during leukocyte extravasation.118 The CD151- or CD9-containing TEMs
include ICAM-1 and VCAM-1 and regulate the membrane distribution and adhesion
activity of ICAM-1 and VCAM-1, thereby promoting leukocyte-endothelium adhesion
and leukocyte tranendothelial migration, the essential steps of leukocyte extravasation.118
During tumor metastasis, the local invasion and infiltration of primary tumor,
tumor-induced angiogenesis, and establishment of metastatic foci involve degradation of
the ECM by matrix metalloproteinases (MMPs), the well-established master regulators of
angiogenesis and tumor progression.122,123 CD151 has been shown to modulate
expression and activation of several MMPs including MMP-2, MMP-7, MMP-9, and
MT-MMP in cancer and endothelial cells.46,49,113-115 In hepatocellular carcinoma (HCC)
patients, high CD151 expression was found to be correlated with elevated expression of
MMP-9, microvessel density (MVD), poor overall survival rate and high cumulative
recurrence after surgery.98 Signal transduction analysis suggests that CD151 induces the
secretion of MMP-9 via an adhesion-dependent c-Jun signaling pathway involving either
the activation of FAK, Src, p38 MAPK, and JNK or the PI3K/Akt/GSK-3β/Snail pathway
in tumor cells, leading to increased tumor cell invasiveness and angiogenesis,
respectively.98,110 The modulatory activity of CD151 toward MMP-9 seems to be
dependent on both integrin-mediated cell-matrix adhesion and homophilic interactions of
CD151 proteins with neighboring cells.98,110 It was also found that CD151-integrin α3β1
complex induces MMP-2 production in breast cancer and epidermal carcinoma cells.46,115
Moreover, in human rectal carcinoma cells and osteoarthritic chondrocytes, CD151
colocalizes with proMMP-7 at the plasma membrane where it physically binds to the
protein through the EC2 domain and induces pericellular activation of proMMP-7.113,114
Another study demonstrated that CD151 regulates MMP-7 expression and co-distributes
with MMP-7 at the leading edge of lamellipodia of migrating epidermal carcinoma
cells.115 These findings, together with the fact that MMP7 is expressed preferentially at
invasive edges in tumors, suggest that CD151 promotes the progression of tumors as well
as other disease such as osteoarthritis by MMP-7-dependent invasiveness and proteolytic
activity.113-115 Endothelial CD151 was also found to associate with MT1-MMP, link
MT1-MMP to integrin α3β1 to form the integrin α3β1/CD151/MT1-MMP ternary
complexes, and modulate the trafficking and enzymatic activity of this
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membrane-anchored proteinase, implying that CD151 is a key regulator for endothelial
homeostasis and angiogenesis.49
TGFβ signaling is an important pathway in modulation of EMT, a process
characterized by loss of cell adhesion, rearrangement of actin cytoskeleton, repression of
E-cadherin expression, and increase of cell mobility. TGFβ signaling is also required for
both physiological processes, such as embryogenesis and wound healing, and
pathological processes, such as tumor procession.121 Upon binding and activating its
receptors, TGFβ1 triggers downstream signaling by inducing the formation and activation
of a Smad2/3/4 transcriptional complex with other co-regulators and thus initiates
re-epithelialization. Smad7 blocks this signaling pathway by competing with Smad2 and
Smad3 to bind TGFβ1 receptors.124 Integrin α3β1 has been recently shown to regulate
TGFβ1 signaling through TGFβ1 downstream effector Smad2 and inhibitor Smad7 and
be required for initiation of re-epithelialization and EMT during wound healing and
pulmonary fibrosis in mice.125,126 Integrin α3β1 could be involved in the Smad signaling
by either mediating the formation of Smad2 transcriptional complex with β-catenin after
phosphorylation or blocking the inhibitory activity of Smad7.125,126 Given the close
functional relevance between integrin α3β1 and CD151, CD151 might also modulate
TGFβ1 signaling-induced EMT during tumor procession. This hypothesis is supported
several lines of evidence. First, loss of CD151 has been shown to result in deficient
wound healing in mice, characterized by retarded re-epithelialization and wound closure,
suggesting that CD151 plays similar roles in tumor EMT. In fact, a recent study revealed
that CD151 functions as a regulator in TGFβ1-induced breast cancer progression.98 Loss
of CD151 attenuates TGFβ1-induced scattering and proliferation of breast cancer cells in
3D Matrigel and correlates with reduced retention of cancer cells in lung vascular bed
and decreased metastasis to lungs.98 However, CD151-dependent regulation in these
processes appears not to involve the activation of Smad2/3 but rather the
compartmentalization of TGFβ type I receptor (TGFβR I) and activation of p38 MAPK.98
Thus, the mechanistic connection of CD151 to TGFβ1-induced EMT is still elusive.
Future studies on the relationship between CD151/integrin α3β1 and
TGFβ1/TGFβR/Smads will be necessary to thoroughly elucidate the roles of CD151 in
tumor procession.

1.3.6.3 CD151 in Hematopoietic Cells
In hematopoietic cells, CD151 expression is mostly restricted to platelets,
megakaryocytes, erythrocytes, dendritic cells, and activated T lymphocytes.67,68,70
Because most hematopoietic cells do not express laminin-binding integrins, the functions
of CD151 in these cells could be independent of laminin-binding integrins.
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A C-terminal deletion mutation of CD151 in humans leads to severe defects in
erythropoiesis,127 underlining a connection between CD151 and proper functioning of
hematopoietic cells. However, CD151-null mice are normal in terms of the development
of hematopoietic cells and proliferation of T lymphocytes.128-130 CD151 also appears to
modulate adhesion of hematopoietic cells such as the homotypic cell-cell adhesion of
erythroleukemia and megakaryoblastic cells.70
CD151 plays important roles in platelet functions. It has been demonstrated that
CD151 is essential for platelet spreading on fibronectin, platelet aggregation responses to
protease-activated receptor 4 (PAR-4) agonist peptide, collagen, and adenosine
diphosphate (ADP), and platelet thrombus formation and stabilization after FeCl3-induced
injury of mesenteric arterioles in mice.129,131 CD151 physically associates with integrin
αIIbβ3, the major integrin in platelets, and is involved in regulation of integrin αIIbβ3
“outside-in” signaling, which supports the notion that CD151 acts as a modulator of
integrin αIIbβ3 signaling and thus contributes to platelet functions.129
In human T lymphocytes, CD151 expression is trans-activated by Tax in response
to human T cell leukemia virus type 1 (HTLV-1) infection and promotes integrin
α5β1-dependent adhesion to fibronectin in HTLV-1-positive T cells.132,133 Moreover,
observations from an in vitro T cell stimulation assay suggest that CD151 is important for
antigen presentation by dendritic cells (DC) to T cells.134 CD151 was found to
specifically regulate the co-stimulation abilities of DC during antigen presentation to
CD4+ and CD8+ T cells without affecting DC development or maturation, suggesting a
regulatory activity of CD151 toward antigen (Ag)-specific cellular immune responses.134
In addition, CD151 may also play a role in the entry of human immunodeficiency virus
type 1 (HIV-1) into macrophages. Recombinant EC2 domains of CD151, as well as
tetraspanins CD9, CD63, and CD81, are capable of inhibiting cellular uptake of HIV-1
virions perhaps by altering the organization of CD4-HIV complexes within the
tetraspanin web, which are required for membrane fusion events.135

1.3.6.4 CD151 in Vascular Endothelium and Its Role in Angiogenesis
In human umbilical vein endothelial cells (HUVECs), intracellular CD151
accounts for up to 66% of the total CD151 and resides in endosomal/lyosomal vesicles,
while CD151 at the cell surface is localized at cell-cell junctions together with CD9 and
CD81, the primary tetraspanins that are associated with CD151.73,80 The
CD151-containing TEM on endothelial cells is critical for proper function of endothelial
cell-cell adhesion proteins such as ICAM-1 and VCAM-1.118 Endothelial cell surface
CD151 is needed for the transendothelial migration of lymphocytes by strengthening the
firm adhesion of lymphocytes to endothelial cells during extravasation.118 In addition,
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CD151-integrin complex regulates endothelial cell migration.73,74,80
Accumulating evidence indicates that CD151 is an important regulator in vascular
morphogenesis. First, CD151 supports the vascular morphogenetic process that
endothelial cell undergo on/in 3-dimensional matrix.73,74,76 Second, CD151
overexpression in heart after myocardial infarction substantially increases the myocardial
microvessel density, suggesting that CD151 promotes neovascularization.89 Third, CD151
knockout mice are deficient in pathologic angiogenesis, based on the observations from
in vivo Matrigel plug, corneal micropocket, and tumor implantation angiogenesis assays
as well as ex vivo aortic ring angiogenesis assay.74 Fourth, CD151 modulates the
expression and enzymatic activity of MMP-9 and MT1-MMP in cancer and endothelial
cells.49,98,122 Because MMP-9 and MT1-MMP are pro-angiogenic, this result supports the
conclusion that CD151 promotes tumor angiogenesis.
However, the mechanisms by which CD151 regulates vascular morphogenesis
remain largely unknown. Mechanistic studies from epithelial and tumor cells indicate that
CD151, through its association with integrin α3β1, regulates E-cadherin-mediated
cell-cell adhesion.116,117 Also, CD151, like its partner integrin α6β4, is a constitutive
component of hemidesmosomes,58 a major cell-matrix adhesion machinery in epidermis.
At the molecular level, CD151 overexpression leads to the PKC- and Cdc42-dependent
actin cytoskeletal reorganization, the process critical for both adhesion and migration,85
while CD151 silencing results in excessive RhoA activity and stress fibers formation,117
suggesting that CD151 plays important roles in the dynamics and activity of the
cytoskeletal machinery in epithelium. In endothelial cells, both overexpression and
knockout studies indicate that CD151 can upregulate eNOS, Akt, and Rac activities,
which are apparently needed for endothelial cell-cell adhesion and angiogenesis.74,89
Endothelial CD151 also promotes the collagenolytic activity and TEM association of
MT1-MMP, an ECM remodeling enzyme involved in angiogenesis.49

1.3.7 CD151 Deficiency in Human and Mouse

1.3.7.1 CD151 Deficiency-related Disease in Human
A truncated human CD151, which is caused by a homozygous nonsense mutation
by a nucleotide insertion (G383) in exon 5 of CD151, has been identified in three
patients.127 This mutation is a frame shift mutation which leads to premature stop codon
and thus results in the deletion of amino acid residues 141-253 covering the EC2 and
C-terminal domain of CD151,127 which are known to be necessary for integrin-binding
and CD151 trafficking, respectively.44,61 Thus, the truncated protein is dysfunctional
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because it cannot associate with integrins. Patients bearing this mutation exhibited
hereditary nephrotic syndrome and developed end stage kidney failure, regional skin
lesions, neurosensory deafness, and severe defects in erythropoiesis.127 The renal defects
are characterized by 1) the thickening and splitting of tubular basement membrane, 2) the
thickening, reticulation, and fragmentation of glomerular basement membrane, and 3) the
clustering of foam cells in the interstitium.127 These findings suggest CD151 is an
important regulator in the organization of basement membrane in human kidney.

1.3.7.2 CD151 Knockout Mouse
To date, several research groups have generated and analyzed CD151 knockout
mice. The published data show that CD151-null mice are viable and fertile with normal
Mendelian inheritance.130 The mice show essentially normal tissue morphology including
the dermal hemidesmosome organization and skin integrity, unaltered hearing ability,
normal blood and bone marrow cell counts, unaffected expression pattern of α3 and α6
integrins in kidney and unchanged expression levels of cell surface α3, α6, β1, and β4
integrin subunits in isolated epidermal keratinocytes.130,136 However, CD151 deletion
causes some mild abnormalities in 1) hematopoietic cell proportion including a slight
increase in the cell numbers of bone marrow promyelocytes and metamyelocytes and a
decrease in lymphocyte number, 2) hemostasis including elevation in average bleeding
time, average blood loss after injury, and incidence of rebleeding occurrences, and 3)
proliferation of T lymphocytes.130
CD151 is expressed by basal keratinocytes in normal skin, and its expression is
upregulated at the tip of the migrating epidermis after wounding, suggesting a role in
wound healing.67,128 Indeed, loss of CD151 results in significantly deficient epidermal
wound healing in mice characterized by impaired re-epithelialization.128 This defect is
very likely due to the aberrant keratinocyte function including proliferation, adhesion,
spreading and migration, and/or disorganization of newly formed basement membrane,
caused by the loss of CD151.128,137
Other observations include the finding that CD151 deletion leads to a strain- and
age-dependent glomerular disease in mouse kidney in FVB strain.130,136 CD151 is highly
expressed in renal glomeruli and co-localizes with α3 integrin at the base of podocyte
foot processes adjacent to the glomerular basement membrane (GBM).136,138 In contrast
to mice lacking α3 integrin who have severe kidney abnormalities leading to birth
lethality, CD151-null mice are neonatally viable and exhibit normal in glomerulus
development.136,139 However, after several weeks or months, the CD151-null mice
displayed mild to severe renal dysfunction, as evidenced by massive glomerular leakage
and GBM thickening accompanied by focal glomerulosclerosis, interstitial fibrosis and
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inflammation, and progressive podocyte loss. These pathological changes partially
resembles the hereditary nephrotic syndrome in patients who bearing the
function-deficient CD151 mutant.127,136,138 The abnormalities might result from weakened
cell adhesion strengthening of podocytes and deficient GBM assembly and maturation,
implicating the roles of CD151 in both podocyte-GBM interaction and GBM
organization.136,138
With respect to vascular system, the absence of CD151 causes the defects in
pathologic angiogenesis in the in vivo Matrigel plug, corneal micropocket, and tumor
implantation assays and in the ex vivo aortic ring assay but not in physiologic
angiogenesis during development, indicating that CD151 plays an important role in
pathologic angiogenesis such as tumor-related angiogenesis and thus contributes to tumor
metastasis.74 Mechanistically, CD151 promotes pathological angiogenesis by, possibly,
regulating the adhesion- and migration-related signaling events including PKB/c-Akt,
e-NOS, Rac and Cdc42 activities in endothelial cells.74
CD151 regulates a variety of cellular and molecular functions based on in vitro
studies, but the ablation of CD151 in mouse does not result in similar or comparable
phenotypic changes in vivo. This can be explained by the complexity of the in vivo
environment or existence of possible compensatory mechanisms for CD151 in vivo.
Future studies using genetically modified animals with function-deficient CD151
mutants, such as the dominant negative mutants, might be necessary to better evaluate the
roles of CD151 in vivo. On the other hand, compared to α3 integrin deletion-derived
deficiencies in wound healing and skin and kidney development, which involves integrin
α3β1-dependent assembly of basement membrane, cell adhesive and migratory abilities,
those occurring with CD151-null mice are less severe but still consistent, suggesting the
functional relevance and similarity between these two firmly associated proteins in
vivo.125-128,136,140

1.4 Summary and Hypotheses
CD151 associates with laminin-binding integrins and functions as a “facilitator”
in integrin-dependent processes and in organization of TEM. It is relatively well
established that CD151 promotes tumor metastasis via its regulatory activities toward
tumor cell motility, cell adhesion, and MMPs. In vascular endothelial cells, the
expression of CD151 is particularly high and throughout vasculature of all human
tissues.67 A regulatory role of CD151 in pathological angiogenesis had also been
determined,74 but the precise mechanisms remain unknown. Previous studies have shown
CD151 regulates E-cahherin-mediated cell-cell adhesion 116,117 and integrin-dependent
cell-matrix adhesion. 58,79,81-83
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We assume that CD151 is involved in regulations of both VE-cadherin-mediated
adherens junctions and integrin-mediated cell-matrix adhesion. We also predict that
CD151 regulates RhoA-mediated cytoskeletal tension. We therefore hypothesize that
CD151 functions as a regulator in coordinating these essential cellular processes and
making endothelial cell adhesion and cytoskeletal tension in balance during angiogenic
vessel formation and stabilization.
In the present study, we will conduct various studies in vitro and in vivo to
evaluate the roles of CD151 in endothelial functions and vascular stability and explore
the intracellular signal transductions. Conclusions drawn from the study will help reveal
the cellular and molecular mechanism by which CD151 regulates angiogenesis and lead
to understanding of the general nature of angiogenesis and vascular stability.
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CHAPTER 2. CD151 STABILIZES VASCULAR NETWORK STRUCTURES AND
CONFINES VASCULAR PERMEABILITY

2.1 Introduction
CD151 and its primary binding partner integrin α3β1 are highly expressed and
tightly associated in endothelial cells.49,80 Integrin α3β1 has been shown to be involved in
many endothelial cell functions and angiogenesis.141-143 Given the function relevance
between the two proteins, CD151 might be also important in vascular functions. In this
chapter, we provide evidence that CD151 is important in stabilizing the vascular network
structures in vitro and promoting vascular barrier function in vivo.
Small interfering RNA (siRNA), which specifically silences protein expression, is
a powerful and accessible tool for study of protein functions in cultured cells.144
Retroviral-based DNA constructs expressing functional small hairpin RNAs (shRNAs)
have been developed and have become the most effective approach to obtain efficient,
long-term and stable loss-of-function phenotypes by siRNA.145-147 A retrovirus-delivered
shRNA system has been reported to knockdown CD151 expression in cancer cells in a
highly specific manner.79,148 Using this system, we generated stable CD151-silenced
endothelial cells and investigated the functions of CD151 in vascular morphogenesis.
Furthermore, we isolated primary lung endothelial cells from CD151-null mice and used
these cells in this study to substantiate our findings.
Matrigel is a commercial available basement membrane preparation from mouse
sarcoma. Previous studies have demonstrated that endothelial cells, after being plated on
the top of Matrigel, are capable of forming an anastonosing network of cable-like
structures, which has been established as an in vitro model system for vascular
morphogenesis.1 We took advantage of this model in our study and observed the
destabilization of vascular structures caused by the loss of CD151.
The blood vessel wall is largely assembled by a endothelial cell layer containing
well-controlled adhesive structures that are required for maintaining tissue
homeostasis.149 Disruption of the endothelial cell barrier by destabilizing the vascular
endothelial adhesive structures elevates vascular permeability and cause plasma
leakage.149,150 To determine the roles of CD151 in vascular permeability in vivo, we
performed a modified Miles assay, a systematical vascular permeability assay,149 using
CD151-ablated mice. We used mustard oil to induce skin irritation and blood vessel
dilation and allow vascular leakage from the skin, and used Evans blue dye to determine
the extent of loss-of-CD151-induced vascular permeability.
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2.2 Materials and Methods

2.2.1 Materials
Matrigel, rat monoclonal anti-mouse PECAM-1 and anti-mouse ICAM-2
antibodies were purchased from BD Biosciences (San Jose, CA). Phalloidin and goat
anti-mouse IgG and anti-rabbit IgG secondary antibodies conjugated to Alex Fluor 488 or
Alex Fluor 594, and sheep anti-rat IgG conjugated to Dynabeads were obtained from
Invitrogen Life Technologies (Carlsbad, CA). Mouse anti-CD151 (5C11) and anti-β1
integrin (TS2/16) monoclonal antibodies were described previously.151 Puromycin,
heparin, mustard oil, Evans blue dye, mineral oil and formamide were obtained from
Sigma-Aldrich (St. Louis, MO). Type I collagenase was from Worthington Biochemical
Corp. (Lakewood, NJ). Dil-Ac-LDL and endothelial cell mitogen was from Biomedical
Technologies Inc. (Stoughton, MD). All other chemicals and reagents were obtained from
Sigma-Aldrich unless otherwise indicated.

2.2.2 Cell Culture and CD151-null Mice
The retroviral packaging GP2-293 cells were cultured in DMEM (Gibco,
Carlsbad, CA) supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA), 100
units/ml Penicillin and 100 μg/ml Streptomycin.
Immortalized human dermal microvascular endothelial cells (HMECs) were
purchased from CDC (Atlanta, GA) and maintained in EBM-2 (Lonza Inc., Allendale, AJ)
supplemented with 10% fetal bovine serum, 100 units/ml Penicillin, 100 μg/ml
Streptomycin, 1 μg/ml hydrocortisone and 10 ng/ml EGF (R&D Systems, Minneapolis,
MN). Human umbilical vein endothelial cells (HUVECs) were obtained from Lonza Inc.
and maintained in EGM supplemented with 10% fetal bovine serum, 100 units/ml
Penicillin, 100 μg/ml Streptomycin, 10 units/ml Heparin and 3 μg/ml bovine brain extract
(Lonza Inc., Allendale, AJ). The endothelial cells were used under passage 10.
The deletion of CD151 in mice was published previously,136 and CD151+/- mice
(FVB strain) were obtained from A. Sonnenberg lab (the Netherlands Cancer Institute,
Netherland). The founder mice were backcrossed more than 5 generations into the
C57BL/6J mouse strain, and genotype analysis was performed by PCR as described
previously.136 A common forward primer has the sequence
“GTCTGACCACCCTATTCATTGTC” (primer 1). The reverse primers are
“GCATGCTGCCTCACTGAAAGC” (primer 2), which was used to detect wild type
alleles, and “GGATGCCAGCAATGCTCTCCA” (primer 3), which was used to detect
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the CD151-deleted alleles. The PCR program was: denaturation at 92ºC for 2 min
followed by 35 cycles of 1 min at 92ºC, 30 sec at 55ºC and 30 sec at 72ºC and a final
extension period of 10 min at 72ºC. 7 to 12 week-old CD151-null mice were used for all
in vivo and ex vivo assays, and were compared with their wild type littermates of same
age and sex.
Mouse lung endothelial cells (MLECs) were isolated as described.74,152 Briefly, 8
week-old mice were euthanized, and mouse lungs were excised, rinsed and minced finely
with scissors. The lung pieces from 2 mice were then dissociated in 50 ml of 1 mg/ml
collagenase (Type I) with gentle agitation for 1 hour at 37ºC. The tissue suspension was
triturated using a 20 cc syringe and then pipetted through a 70-μm cell strainer to remove
the un-dissociated tissue clumps. Primary endothelial cells were isolated from the
pulmonary cell suspension using anti-mouse PECAM-1-coated magnetic Dynabeads.
After a 5-day culture period, the cells underwent another selection using anti-mouse
ICAM-2-coated Dynabeads to enrich the endothelial cell population. The isolated cells
were cultured in MDCB131 medium (Gibco, Carlsbad, CA) supplemented with 10% fetal
bovine serum, 100 units/ml Penicillin, 100 μg/ml Streptomycin, 5 μg/ml endothelial cell
mitogen, 10 U/ml heparin, and were used between passages 1 and 3.
The endothelial cell properties from the above preparation were confirmed by the
incorporation of Dil-Ac-LDL (acetylated low density lipoprotein labeled with
1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate).153 In brief, the
isolated primary cells were incubated with complete growth media containing 10 μg/ml
Dil-Ac-LDL for 4 hours at 37ºC. The media were then removed, and cells were washed
with probe-free media. Then incorporation of the fluorescent probe in vascular
endothelial cells was detected by flow cytometry after cell trypsinization.

2.2.3 Retroviral Production
A retrovirus-delivered shRNA system, which has been developed to knockdown
human CD151 expression in a highly specific manner79,148, was used in this study to
establish stably CD151-silenced endothelial cells. As shown in Figure 2-1, the
CD151-silencing (CD151 KD) pSIREN construct contains a shRNA-expressing cassette
targeting the sequence “AGTACCTGCTGTTTACCTACA” in exon 2 of human CD151
transcript, and the non-silencing (MOCK) construct contains a sequence
“GCGAGACCATGCCTCCAACAT” which is homologous to sequence in the exon 6 of
human CD151 mRNA but does not have gene silencing effect.79,148 To produce CD151
KD and MOCK shRNA construct-containing retroviruses, equal amount of pSIREN
construct and pVSV-G retroviral coat protein expression vector were co-transfected with
into GP2-293 retroviral packaging cells using transfection reagent Lipofectamine 2000
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Figure 2-1. ShRNA construct map.
The CD151 KD or MOCK shRNA oligonucleotide was synthesized and subcloned into
the pSIREN RetroQ vector.79,148 The CD151-silencing (CD151 KD) shRNA sequence
targets the sequence “AGTACCTGCTGTTTACCTACA” in exon 2 of human CD151
transcript. The non-silencing (MOCK) shRNA sequence
“GCGAGACCATGCCTCCAACAT” is homologous to sequence in the exon 6 of human
CD151 mRNA but does not have gene silencing effect.79,148
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(Invitrogen Life Technologies, Carlsbad, CA). After 4 hours, cells were replenished with
fresh DMEM complete medium and cultured for 48 hours. Virus-containing medium was
then 0.45-μm filtered and stored at -80ºC for further experiment.

2.2.4 Retroviral Transduction and RNAi
HMECs or HUVECs were seeded at 70% confluence one day prior to virus
exposure. Then virus-containing medium and polybrene (final concentration 5 μg/ml)
were mixed and added to the cell culture dishes. The cells were incubated at 4ºC for 30
min, then switched back to 37ºC and incubated for 24 hours. On the second day, cells
were feed by fresh medium for a further 24 hours and underwent selection with 2 μg/ml
puromycin for puromycin-resistant cells. Stable transductants were obtained after
selection, and then subjected to cell sorting to get rid of any RNAi-escaping cell
population using anti-CD151 mAb (5C11) as probe. The sorted cells were maintained
with 0.2 μg/ml puromycin. Cells transduced with the non-silencing shRNA-containing
viruses served as MOCK cells.

2.2.5 Flow Cytometry and Immunofluorescence
For flow cytometry, suspended cells were incubated with 1 μg/ml of various
primary Abs including anti-human CD151 (5C11), CD9 (C9BB), CD81 (M38), and
integrins α3 (A3-IVA5), α5 (A5-PUJ2), α6 (A6BB), αV (P3G8) and β1 (TS2/16) for 1
hour on ice followed by 3 washes with PBS. Then cells were incubated with appropriate
FITC-conjugated secondary antibody for 30 min followed by 3 more washes. The
absence of CD151 on cell surface, as well as expression of other cell surface proteins,
was analyzed by a flow cytometer (BD Biosciences).
Immunofluorescence was performed as described with modifications.44 In brief,
cells were fixed with 3% paraformaldehyde for 15 min, permeablized with 0.1% Brij98
for 2 min and blocked for 30 min, and then incubated with 5C11 at 4ºC overnight. Then
cells were incubated with Alexa Fluor 594-conjugated secondary antibody and Alexa
Fluor 488-conjugated phalloidin for 1 hour. Staining of CD151 and actin in
CD151-silenced cells and MOCK cells were visualized using a fluorescent microscope.

2.2.6 3D Capillary Formation Assay
Matrigel was thawed and maintained as a liquid on ice. Appropriate amount of
Matrigel was added to 48-well plates, in duplicate, for regular photography, or in glass
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bottomed cell culture dishes (1.0 cm in diameter of the glass bottom cell culture area) for
time-lapse video microscopy, and incubated at 37ºC for 1 hour. HMEC transfectants or
the mouse lung endothelial cells were seeded on the top of Matrigel in a 60,000/well
density. The cellular cables were photographed at different time points or recorded by
time-lapse video microscopy every 5 min for 72 hours. The total cable length and/or the
number of cable cord-enclosed regions within the photographs and videos were
calculated and presented as quantitative data for the cable network structures.

2.2.7 Modified Miles Assay
The modified Miles assay, which is used to determine vascular permeability in
vivo, was described previously.149 Evans blue dye (30 mg/kg in 100 μl PBS) was injected
i.v. into 12 week-old male WT and CD151 KO mice through the retro orbital sinus using
a 30-gauge needle. The 5% mustard oil in mineral oil (v/v) or mineral oil alone was
immediately administrated on the dorsal and ventral surfaces of the ear. The
administration was repeated one more time 15 min later. After Evans blue had circulated
for 30 min, the mice were anesthetized and perfused with 10 ml PBS. Mouse ear was then
photographed, excised, dried and weighed. Evans blue dye was extracted in 1 ml
formamide overnight at 55ºC and its content in the ears was quantified by measuring the
absorbance at 610 nm with a spectrophotometer.

2.3 Results

2.3.1 Silencing CD151 Expression in Endothelial Cells
A retrovirus-delivered shRNA system has been developed to knockdown human
CD151 expression in a highly specific manner.79,148 We have established 1) the stable
transductant of CD151 knockdown (CD151 KD) and 2) the control transductant (MOCK)
in HMECs. Compared with the parental HMECs and MOCK cells, the CD151 KD cells
displayed 1) a near total loss of CD151 expression at the cell surface in flow cytometry
(Figure 2-2A) and 2) remarkable downregulation of CD151 expression in
immnofluorescence assays (Figure 2-2B). In addition, HUVEC cells with efficient
CD151-silencing were also successfully obtained by the shRNA retroviral transduction
(data not shown).
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Figure 2-2. Silencing of CD151 in HMECs.
HMEC cells were transduced with CD151 knockdown (KD) and MOCK
shRNA-encoding retroviruses, followed by selection with 2 μg/ml puromycin. CD151
KD transductants were then subjected to cell sorting to get rid of any RNAi-escaping
cells, and the silencing efficiency was determined by (A) flow cytometry and (B)
immunofluroscence staining using CD151 mAb (5C11). Bar = 50 μm.
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2.3.2 CD151 Silencing Does Not Alter Cell Surface Expression of CD151-related
Integrins and Tetraspanins
CD151 physically and/or functionally associates with integrins and other
tetraspanins to form TEMs.31 Hence, the expressions of these transmembrane proteins are
important for CD151 functions in endothelial cells. We analyzed the cell surface
expressions of various integrins and tetraspanins related to CD151 using flow cytometry
and found no significant differences in the expressions of integrins α3, α5, α6, αV, and β1
and tetraspanins CD9 and CD81 in HMEC-parental, -MOCK, and -CD151 KD cells
(Table 2-1). These results indicate the expressions of these integrins and tetraspanins in
HMEC and suggest that neither retroviral transductions nor CD151 knockdown alters the
cell surface expressions of these CD151-relevant proteins. The results also confirm that
the CD151-silencing system is highly specific.

2.3.3 Identification of Isolated MLECs
Dil-Ac-LDL is a vascular endothelial cell and macrophage-specific fluorescent
dye. After uptake of Dil-Ac-LDL, the lipoprotein is degraded within lysosome and the
intracellular membranes of the cells are labeled with Dil (a PE-like fluorescent probe).153
Macrophages can be differentiated from endothelial cells because they are more brightly
labeled. Thus, we used Dil-Ac-LDL to identify the primary endothelial cells we prepared
from mouse lung using anti-mouse PECAM-1 and ICAM-2, the two endothelial
cell-specific markers, monoclonal antibodies. As shown in Figure 2-3, most of the cells
(more than 90%) isolated from both WT and CD151 KO mouse lung are single peaked
and labeled with Dil at relatively low level, indicating that 1) no contamination of
macrophages, and 2) the high purity of vascular endothelial cells in the isolated cells.
These results show that we have obtained mouse WT and CD151 KO primary endothelial
cells with high purity.

2.3.4 CD151 Stabilizes Vascular Network Structures Formed by Endothelial Cells on
Matrigel
In this study, we used the model system “3D capillary formation on Matrigel” to
evaluate the roles of CD151 in vascular morphogenesis. As shown in Figure 2-4, both
HMECs and MLECs initially formed similar capillary-like network structures on
Matrigel regardless of the presence and absence of CD151 expression. Neither HMECs
nor MLECs show significant difference in total cable length between CD151 expressing
(HMEC-MOCK and MLEC-WT) and non-expressing (HMEC-CD151 KD and
MLEC-CD151 KO) endothelial cells, suggesting the initial formation of capillary
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Table 2-1. The surface expression of integrins and tetraspanins on HMEC-parental,
-MOCK, and -CD151 KD cells.
Transductants
Mouse IgG
CD151
CD9
CD81
Integrin α3
Integrin α5
Integrin α6
Integrin αV
Integrin β1

Parental
220 ± 39
3,098 ± 113
10,156 ± 1,132
6,644 ± 414
5,431 ± 445
1,018 ± 81
1,452 ± 291
1,594 ± 583
16,747 ± 763

MOCK
226 ± 37
3,244 ± 221
11,018 ± 764
7,297 ± 760
5,618 ± 655
1,110 ± 96
1,479 ± 346
1,990 ± 960
17,878 ± 662

CD151 KD
218 ± 53
290 ± 56
10,245 ± 1,609
7,814 ± 833
4,801 ± 221
1,012 ± 197
1,529 ± 207
1,447 ± 428
18,072 ± 531

Note: The flow cytometry analysis of HMECs was performed using mAbs against human
tetraspanin CD151 (5C11), CD9 (C9BB), or CD81 (M38) and integrin α3 (A3-IVA5), α5
(A5-PUJ2), α6 (A6BB), αV (P3G8), or β1 (TS2/16) to confirm the absence of CD151 on
cell surface as well as expression of other cell surface proteins. The numbers represent
the mean fluorescence intensities ± standard deviation from 3 independent experiments.
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Figure 2-3. Identification of MLECs.
The isolated lung primary endothelial cells were incubated with complete growth media
containing 10 μg/ml Dil-Ac-LDL for 4 hours at 37ºC. Cells were trypsinized and washed,
and the incorporation of the fluorescent dye by cells was analyzed by flow cytometry.
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Figure 2-4. Loss of CD151 impairs vascular stability.
(A) Silencing of CD151 expression disrupted the capillary-like structures on Matrigel.
HMEC-Mock and -CD151 KD cells were plated on Matrigel, and photographed at the
indicated time points. (B) Deletion of CD151 in mice impairs angiogenesis in vitro. Mice
lung endothelial cells (MLEC) were isolated from wilt (WT) and CD151 null (CD151
KO) mice and employed in the Matrigel cable formation assay. Representative
photographs are shown for HMECs and MLECs. Bar = 250 μm. * P < 0.01.
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network is not affected by the loss of CD151. However, as time goes by, CD151-silenced
and CD151-null cells cannot maintain the cable-like structures. Compared with the
network structure formed by CD151-expressing cells (HMEC-MOCK and MLEC-WT),
the ones formed by CD151-silenced (HMEC-CD151 KD) and CD151-null
(MLEC-CD151 KO) cells were markedly and largely disrupted at 18 hour, respectively.
In CD151-silenced HMECs, the networks became completely lost at 54 hour. The
quantitative results for the cable-like structures reveal the disruption caused by the loss of
CD151, as indicated by the remarkable decrease in total cable length of the cable network
in HMEC-CD151 KD (Figure 2-4A) and MLEC-CD151 KO cells (Figure 2-4B).
Using DIC time-lapse video-microscopy, we found that HMEC-MOCK and
-CD151 KD cells were attached and spread equally well and actively migrated around
soon after being plated on Matrigel (Supplement Movies). In the following 2-4 hours,
both MOCK and CD151 KD cells assembled into networks of cable structures to the
similar extent, suggesting that CD151 is not required for endothelial cells patterning into
vascular structures. In general, MOCK cells can maintain the network structures for
several days though the cables become thicker and denser. In contrast, CD151 KD cells
cannot maintain the network structure, and the cable networks were continually
contracting and eventually broke into disconnected cell clumps. The quantitative results
of the capillary structures from the videos, presented as the number of circled regions
formed by the cable cords at different time point (Figure 2-5), show significant difference
between MOCK and CD151 KD cells. MOCK cells formed much more cable
cord-enclosed areas at ~ 5 hour and afterwards than CD151 KD cells, indicating MOCK
cells form more stable network structures than CD151 KD cells, and suggesting loss of
CD151 unstabilizes the vascular network structures formed by endothelial cells.
Together, these results demonstrate that CD151 stabilizes the newly formed
endothelial network structures without affecting the initial formation of the vascular
structures.

2.3.5 CD151 Regulates Vascular Permeability
To substantiate the in vitro finding, we then analyzed the vascular stability of
CD151 knockout mice,136 by performing a modified Miles assay, which examines
microvascular permeability during inflammation.149 As shown in Figure 2-6, compared
with mineral oil alone group, the 5% mustard oil-treated group shows substantial vascular
permeability on mouse ear after 30-min circulation of Evans blue dye, as indicated by
dermal leakage of the blue dye in the ear. On the other hand, the level of dermal dye
leakage is significantly higher in CD151 KO mice than that in WT mice, based on the
quantitative data from 30 mice. This data suggests that vascular permeability is
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Figure 2-5. Quantification of the cable network in the time-lapse movies.
The number of cable cord-enclosed regions in the movies was counted at different time
points.

Figure 2-6. Loss of CD151 increases vascular permeability in mice.
Evans blue dye (30 mg/kg in PBS) were injected in 12 week-old male mice i.v.. Mustard
oil in mineral oil (5% v/v) or mustard oil alone was applied to the dorsal and ventral
surfaces of the ears twice, at 0 min and 15 min later. After 30 min circulation, the mice
were perfused with PBS. Then dye leakage area at the ventral surface of the ear was
photographed, and the content of dye in ears was determined after extraction. Bar = 1 mm.
* p < 0.05.
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markedly elevated in CD151 KO mice, compared with wild type littermates upon the
inflammatory factor mustard oil treatment. We conclude that CD151 is important in
preventing vascular leakage and maintaining vascular integrity and stability.

2.4 Summary
In order to investigate the roles of CD151 in vasculature, we established stably
CD151-silenced endothelial cell lines using a retrovirus-delivered shRNA. A near total
loss of CD151 expression was obtained in these cell lines. We found the CD151 shRNA
system functions in a highly specific manner since CD151 silencing does not alter the cell
surface expression levels of its related integrins and other tetraspanins. In addition, we
prepared lung primary endothelial cells from WT and CD151 KO mice for further
mechanistic studies.
We took advantage of the in vitro model system, 3D capillary formation on
Matrigel, to evaluate the biological functions of CD151 in vascular morphogenesis We
have found that loss of CD151 alters vascular stability. In the absence of CD151,
endothelial cells can initiate the formation of capillary network structures on Matrigel;
however, as time goes by, the vascular structures cannot be sustained. Furthermore, we
performed an in vivo microvascular permeability assay, and observed significantly
elevated vascular permeability induced by mustard oil in CD151 KO mice. Collectively,
our results demonstrated that CD151 stabilizes vasculatures without affecting the initial
formation of the vascular network structures.
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CHAPTER 3. CD151 STRENGTHENS ENDOTHELIAL CELL-MATRIX
ADHESION WITHOUT AFFECTING CELL DEATH AND MOTILITY

3.1 Introduction
Angiogenesis is a complex process involving endothelial cell activation and
migration from pre-existing blood vessels, cell proliferation and assembly of endothelial
cells into an well-controlled intercellular structures and attachment on basement
membrane.2,3,154 We have shown loss of CD151 disrupts the maintenance of the
capillary-like structures on 3D Matrigel and results in aberrant vascular permeability in
vivo. From the results shown in Figure 2-4, the time-lapse videos and other studies
demonstrating that CD151 plays important roles in cell migration, cell-cell adhesion, cell
morphogenesis, and adhesion strengthening in epithelial or tumor cells, we predict that
CD151 might be also important in the basic endothelial cellular processes including cell
death, cell motility, cell-matrix adhesion, cell-cell adhesion and cytoskeletal tension, and
thus participate in the regulation of vascular stability. In Chapters 3 to 5, we will examine
the roles of CD151 in these cellular processes and the associated signaling events and
define the precise mechanisms by which CD151 regulates vascular stability.
Since endothelial cell growth and motility play important roles in
angiogenesis,2,3,154 we first performed a set of assays for cell death and cell motility to
evaluate the roles of CD151 in these cell events.
Cell-matrix adhesion is primarily mediated by integrins. After being engaged with
ECM, integrins induce formation of focal adhesions and cortical actin cytoskeleton
assembly.155,156 In focal adhesions, integrins associate with a group of focal
adhesion-associated adaptor proteins, such as paxillin and focal adhesion kinase (FAK),
and the actin cytoskeletal “crosslinker” proteins including vinculin, α-actinin and talin to
mediate the anchorage of actin filaments.155-158 To elucidate the role of CD151 in
endothelial cell-matrix adhesion, we first performed conventional, short-term, static
cell-matrix adhesion assay to investigate integrin-mediated early attachment of
endothelial cells onto various matrices. Furthermore, we employed traction force
microscopy (TFM) to determine the effect of loss of CD151 on cell-matrix adhesion in
high resolution. Also as known, within focal adhesions, integrins serve as the
transmembrane mechanical linkages between ECM and cytoskeleton by binding to the
ECM components with their extracellular domains and to cytoskeletal proteins with the
cytoplasmic domain of the β-subunit.155,156 Thus, the soundness of focal adhesions is
dependent not only on the ligand binding affinity of integrins but also on their
intracellular cytoskeletal connections. Therefore, we also analyzed connections of β1
integrin with actin cytoskeleton to obtain in-depth mechanistic information. In addition,
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because CD44 binds to hyaluronan, connects with actin cytoskeleton through
ezrin/radixin/moesin (ERM) proteins, a different type of protein “linkers” for the
anchorage of cytoskeleton, and mediates cell-matrix adhesion,159-162 we also investigated
the effect of CD151 on CD44 expression.

3.2 Materials and Methods

3.2.1 Materials
Propidium iodide (PI) was purchased from Calbiochem (San Diego, CA).
Fibronectin and laminin 1 were obtained from Invitrogen Life Technologies (Carlsbad,
CA). Laminin 5 was described previously.163 Fluorescent latex beads (FluoSpheres 0.2
μm) were purchased from BD Biosciences (San Jose, CA). Sulfo-SANPAH was from
Thermo Fisher Scientific (Rockford, IL). Mouse anti-β-tubulin mAb was from
Sigma-Aldrich (St. Louis, MO). Mouse anti-CD44 mAb was purchased from BD
Biosciences (San Jose, CA). Goat anti-mouse and anti-rabbit IgG antibodies conjugated
to horseradish peroxidase (HRP) were obtained from Amersham Biosciences Corp.
(Piscataway, NJ). Aprotinin and leupiptin were from Roche Diagnostics (Indianapolis,
IN). All other chemicals and reagents were obtained from Sigma-Aldrich unless
otherwise indicated.

3.2.2 Cell Death Assay
PI staining and flow cytometry were performed to analyze cell death. HMEC
transductants were plated in 6-well plate which was precoated with diluted Matrigel.
After cultured for 18 hours or 54 hours, cells were trypsinized and washed with PBS 3
times. Then cells were resuspended in PI buffer (1 μg/ml in PBS containing 2% FBS) and
incubated on ice for 45 min in dark. Dead cells were stained brightly red by PI and were
analyzed by FACS analysis.

3.2.3 Cell Motility Assays
For transwell migration assay, the outer side of the transwell polycarbonate filter
(0.8-μm pore, Costar) were precoated with various ECM components (10 μg/ml
fibronectin, 10 μg/ml laminin 1 and 2 μg/ml laminin 5) at 4ºC overnight and then blocked
by 0.1% heat-inactivated (HI) BSA for 1 hour at 37ºC. 2,000 HMEC cells suspended in
300 μl serum-free medium containing 0.1% HI BSA, in triplicate, were then plated into
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the upper chamber of the transwell filter. 300 μl of complete medium were added into the
lower chamber as attractive medium. Cells were allowed to migrate at 37ºC for 4 hours.
Then those cells staying in upper chamber were removed with cotton swabs and those
cells that migrated to the side towards lower chamber were stained and counted.
Wound healing assay was performed as described.164 In brief, HMEC-MOCK or
-CD151 KD cells were plated in 24-well plate and cultured until confluence. Then cells
were starved for 24 hours before wound formation. Wounded areas were created in
monolayer of cells by scraping with a 200-μl pipette tip. The wounded cell monolayer
was cultured in serum-free media and the changes of cell-free area were photographed at
different time points under a microscope connected with a digital camera.

3.2.4 Cell-matrix Adhesion Assay
Cell-matrix adhesion assay was performed in a 96-well format as described.165
Briefly, the wells of 96-well plates were precoated with 10 μg/ml fibronectin, 10 μg/ml
laminin 1, 2 μg/ml laminin 5 or diluted Matrigel at 4ºC overnight and then blocked by
0.1% HI BSA for 1 hour at 37ºC. 10,000 HMEC cells suspended in 100 μl serum-free
media containing 0.1% HI BSA were plated into the wells in triplicates. After 35-min
incubation at 37ºC, non-adherent cells were removed by 3 gentle washes with PBS. The
adhered cells were photographed and counted from each photograph.

3.2.5 Traction Force Microscopy
The cellular traction forces were measured by traction force microscopy based on
the experimental and computational advances as described previously166,167 with
modifications.
Briefly, HMECs were placed on the fluorescent latex beads-embedded
polyacrylamide (PAA) gel, which were coated with sulfo-SANPAH to conjugate
fibronectin (10 µg/ml in PBS) or laminin 1 (10 µg/ml in PBS), and allowed to attach and
spread for 12-24 hour prior to image. Individual cells were imaged with both phase
contrast and confocal microscopy to capture the positions of the fluorescent beads under
and around cell area while the cell exerts traction forces on PAA gel upon attaching. The
cells were then detached by trypsinization and a second confocal image of the
bead-embedded substrate was taken to capture the positions of the fluorescent beads in
the absence of cellular traction forces. Then the displacement field caused by cellular
traction forces was obtained from the High Density Mapping software analysis166 of the
two images using the phase correlation method, which is based on the Fourier shift
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principle. Finally, the displacement data was calculated into the traction field using the
Fourier-transform traction cytometry (FTTC) method as described.167,168
The traction force contour plots were generated from the traction field data for
each cell area. The maximum traction force within each cell area was calculated as the
maximum traction force magnitude value averaged by the surrounding vector magnitudes
after a peak smoothing algorithm processing. The average perimeter stress was calculated
as the average of the reaction force values found along the perimeter of the cell. For each
transfectant, 10-15 cells were measured, and comparisons were made for both maximum
and average traction stress magnitudes using a non-parametric Mann-Whitney test, with
p < 0.05 indicating significant difference.

3.2.6 TIRF Microscopy
HMEC transductants were plated on glass bottom dishes and cultured overnight.
Cells were then fixed with freshly prepared 3% paraformaldehyde for 15 min without
permeabilization, blocked with 20% goat serum for 30 min, and incubated with either
anti-α3 integrin (A3-IVA5) or anti-CD9 (C9BB) mAb at 4ºC overnight. Then cells were
incubated with Alexa Fluro 488-conjugated secondary antibody for 1 hour. Staining of α3
integrin and CD9 at basal surface of CD151-silenced cells and MOCK cells were
analyzed using a TIRF microscope.

3.2.7 Detergent Solubility Assay for β1 Integrin
To analyze the connection of β1 integrin to actin cytoskeleton, the detergent
solubility assay were performed as described previously.85 In brief, HMEC transductants
were cultured overnight on fibronectin-precoated dishes and then solubilized with 0.15%
Triton X-100 in HEPES buffer on ice for 10 min with gentle pipetting. After
centrifugation at 100,000 g for 30 min, the supernatants were mixed with equal volume
of 2 X Laemmi buffer and labeled as the soluble fractions. The pellets were dissolved in 1
X Laemmi buffer and labeled as the detergent-insoluble fractions. Total cellular was
extracted by 1 X Laemmi buffer from uncentrifuged raw cell lysates. Integrin β1
distributed in soluble and insoluble fractions as well as total cellular β1 integrin was
resolved by reducing SDS-PAGE. The separated proteins were then transferred to 0.45
μm PVDF membrane and subjected to immunoblotting. For immunoblotting, the
membrane were blocked with 5% non-fat milk at room temperature for 30 min, probed
with β1 integrin mAb (TS2/16) at 4ºC overnight, and developed with HRP-conjugated
secondary antibody followed by chemiluminescence.
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3.2.8 TS2/16 Antibody Treatment
HMEC transfectants were pre-incubated with 1 μg/ml TS2/16, a β1
integrin-activating antibody, in cell culture medium for 1 hour on ice, and then used in
3D capillary formation assay as described in Section 2.2.6. The cells were replenished
with fresh medium containing 1 μg/ml TS2/16 every 8 hours and photographed at
indicated time points. No antibody- and anti-CD 71 antibody (an isotype-matched
mAb)-treated cells served as negative controls. Total cable length and number of circled
regions were counted and used as quantitative data for the cable network structures.

3.2.9 Analysis of CD44 Expression
The mRNA expression levels of CD44 in HMEC transfectants were determined
by quantitative real time-PCR (qRT-PCR). Total RNA was extracted from HMEC
transductants in triplicates using RNase Protect Mini Kit (Qiagen, Valencia, CA),
according to the manufacturer’s instructions. RNA concentration was determined by
measuring the absorbance at 280 nm using a NanoDrop ND-1000 spectrophotometer.
Total mRNA was then immediately reverse-transcribed into cDNA using a Taqman
Reverse Transcription Reagent Kit (Applied Biosystems, Carlsbad, CA). RT-PCR was
performed on cDNA template with a Roche Light Cycler instrument according to
manufacturer’s instruction. An intron-spanning 92 nt amplicon of human CD44 gene was
obtained from qRT-PCR using the forward primer “gtgttcgtgccagctatgac” and reverse
primer “ccatcattgattgtctccacac”, which are located at CD44 exons 1 and 2, respectively.
The internal control RT-PCR was set to the reference gene, human TATA Boxing Protein
(TBP), for the cDNA sample using forward primer “GACACCATGGACAAGTTTTGG”
and reverse primer “CGGCAGGTTATATTCAAATCG”. The Ct (cycle threshold) values
were obtained from every PCR test.169 The expression levels of CD44, presented as
relative mRNA levels, were calculated according the equation as:
E = 2–[Ct(I)-Ct(R)]
where E is defined as relative mRNA expression level.169 Ct(I) and Ct(R) are the Ct
values of gene of interest and of reference gene, respectively. Then data were normalized
by setting the relative CD44 mRNA levels in HMEC-MOCK cells as 1, and comparison
was performed between MOCK and CD151 KD cells. Cell surface and total cellular
levels of CD44 protein was analyzed by flow cytometry and immunoblotting using CD44
mAb, respectively.
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3.3 Results

3.3.1 CD151 Does Not Affect Cell Death
Decreased stability of CD151-silenced and -ablated endothelial network may
result from increased apoptosis and reduced cell proliferation rate. We assessed the effect
of CD151 silencing on cell survival. As shown in Figure 3-1, both HMEC-MOCK and
-CD151 KD cells exhibited almost full viability after being plated on Matrigel for 18
hours or 50 hours, indicating that the vascular instability in the absence of CD151 is not a
result of cell death. Study from elsewhere demonstrated that CD151 removal has no
impact on endothelial cell proliferation.74

3.3.2 Endothelial Cell Migration Remains Unchanged in the Absence of CD151
CD151 promotes cell movement in a variety of cell systems.72,79 However, the
loss of CD151 expression in HMECs did not markedly affect cell migration. Neither the
ability of cell to migrate onto fibronectin, laminin 1, and laminin 5 in transwell migration
assay (Figure 3-2A) nor the cell motility in wounding healing assay (Figure 3-2B) was
significantly altered in CD151 KD cells, compared to MOCK cells, suggesting that
endothelial cell migration is not responsible for CD151-dependent maintenance of
endothelial network structures during HMEC morphogenesis.

3.3.3 CD151 Is Needed for Optimal Endothelial Cell-matrix Adhesiveness
To fully understand the functions of CD151 in endothelial cell-matrix adhesion,
we first evaluated the effect of loss of CD151 on the early adhesion of HMECs on
various ECM using the conventional cell-matrix adhesion assay. As shown in Figure
3-3A, more MOCK cells were resistant to the washing shear forces than CD151 KD cells
35 min after being plated on laminin 5, suggesting loss of CD151 diminished cell
adhesiveness at the early stage of endothelial cell adhesion onto laminin 5. However, no
significant decreases in early adhesion onto fibronectin, laminin 1 and Matrigel were
found in CD151 KD cells. This result is consistent with earlier observations in other
cells74,79 and underlines that CD151 only markedly attenuates the early adhesion
dependent on laminin 5-binding integrins α3β1 and/or α6β4 to a magnitude detectable via
shear force-induced detachment.
The traction forces, that take place between cells and the surrounding
environments, are generated by the actomyosin cytoskeleton and transmitted to the
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Figure 3-1. Loss of CD151 does not affect endothelial cell viability.
HMEC transductants were plated on diluted Matrigel-precoated 6-well plate and cultured
for 18 or 54 hours. Cells were incubated with 1 μg/ml PI, and the stained cells were then
analyzed by flow cytometry to analyze dead and live cells.
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Figure 3-2. Loss of CD151 does not alter endothelial cell migration.
(A) Transwell migration assay. 2,000 HMEC-MOCK and -CD151 KD cells were placed
in the transwell inserts precoated with fibronectin, laminin 1 or laminin 5, and allowed to
migrate through the filters. Migrated cells were then stained and counted. Data were from
4 independent experiments. (B) Wound healing assay. HMEC transductants were cultured
in 24-well plate until confluence. Then cells monolayers were starved, wounded and
cultured in serum-free media. The wound area were monitored and photographed at
indicated time points. Bar = 400 μm.
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Figure 3-3. Loss of CD151 diminishes endothelial cell-matrix adhesiveness.
(A) Cell-matrix adhesion assay. HMEC transductants were seed on ECM substrate-coated
wells, and settled at 37ºC for 35 min. Non-adherent cells were then removed by gentle
washes. The adhered cells were counted. Error bars represent standard errors from four
independent experiments. * p < 0.01. (B) Traction force microscopy. Cells were placed
on fibronectin- or laminin 1-coated fluorescent beads-embedded PAA gel. Traction forces
exerted by cells cause deformation of the beaded gels. The deformation is characterized
by the two-dimensional displacement of the beads and is translated into the traction field
after correlation of deformed and undeformed gels. Left: phase contrast images and
traction field contour plots of HMEC transductants plated on fibronectin-coated PAA
gels. Bar = 10 μm. Right: adjusted maximum and perimeter traction forces of HMEC
transductants on fibronectin and laminin 1. ** p < 0.05.
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underlying substrate through focal adhesion and close contacts and represents cell-matrix
adhesiveness.170,171 Cells placed on elastic substrate could cause deformations of the
flexible substrate such as PAA gels due to the traction forces upon cell adhesion.170,171 By
detecting the levels of deformations on the fluorescence-beaded gels together with
imaging and computational advances,170,171 we are able to measure traction forces and
quantify the strength of cell adhesion. As shown in Figure 3-3B, compared with MOCK
cells (n = 15), CD151 KD cells (n = 11) plated on fibronectin-coated gels are
significantly decreased in generation of both maximal traction forces (32.5 Pa in CD151
KD versus 85.6 Pa in MOCK) and perimeter traction forces (8.3 Pa versus 20.5 Pa). On
laminin 1-coated gels, 6 out of 10 MOCK cells and 9 out of 10 CD151 KD cells exhibited
traction stress below the threshold of measurement. Because the maximum stresses in a
majority of cells are not measurable, a statistical comparison was not performed. But the
undetectable traction force found in more CD151 KD cells implies that CD151 silencing
leads to less traction force on laminin 1. Hence, CD151 is needed for the strengthening of
cell-matrix adhesion on both fibronectin and laminin 1.

3.3.4 CD151 Does Not Determine Physical Properties of α3 Integrin and CD9 in
Endothelial Cell-matrix Interface
CD151 associates with integrins, such as integrin α3β1, and tetraspanins, such as
CD9, in TEM.31 To determine how the loss of CD151 expression diminishes the
strengthen of cell-matrix adhesion, we investigated the physical properties of TEM
components integrin α3β1 and CD9 at the basal plasma membrane of endothelial cells
using TIRF microscopy, which visualizes the molecular distribution and organization at
the cell and matrix interface. As shown in Figure 3-4, at the basal cell surfaces of the
majority of HMEC-MOCK and -CD151 KD cells, CD9 largely localizes at the peripheral
regions whereas integrin α3β1 relatively evenly distributed across the pericentrolar area.
The fluorescent particles of integrin α3β1 and CD9 exhibit no distinguishable difference
in term of number, size, morphology, and distribution between HMEC-MOCK and
-CD151 KD cells, suggesting that CD151 does not modulate cell-matrix adhesion by
altering these biophysical properties of TEM.

3.3.5 CD151 Regulates Glycosylation of α3 Integrin
CD151 was shown to be required for glycosylation of integrin α3β1 in epithelial
cells. The glycosylations at the light chain of α3 integrin subunit result in faster
migrating rate of the protein in SDS-PAGE.62 In endothelial cell, we observed similar
phenomena. As shown in Figure 3-5, in HMEC-MOCK cells, α3 integrin light chain
resolved as closely spaced multi-bands corresponding to the glycosylated protein on the
62

43

Figure 3-4. TIRF microscopy.
HMEC transductants was fixed without permeabilization, probed with α3 integrin or CD9
mAb and Alex488-conjugated secondary antibody, and visualized by a TIRF microscope.
Shown are representative TIRF images (upper panel) and quantitative results of the size
and numbers of fluorescent detective particles (lower panel) in individual cells (n = 20).
Bar = 10 μm.
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Figure 3-5. Loss of CD151 inhibits glycosylation of α3 integrin.
HMEC-MOCK and -CD151 KD cell lysates were resolved by 12% SDS-PAGE under
reducing conditions and analyzed by immunoblotting using specific Abs for α3 integrin
(D23) and β-tubulin.
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lower positions and the unglycosylated form on top with equal intensity. In contrast,
integrin α3 light chain of CD151-silenced HMECs is prominent in the top band,
suggesting loss of CD151 blocks glycosylation of α3 integrin and showing consistence
with early observation.62 This result points to a potential novel mechanism by which
CD151 regulates endothelial cell-matrix adhesion strengthening, i.e. CD151 might
optimize the adhesive properties of integrin α3β1 by modulating glycosylation of the
integrin.

3.3.6 CD151 Strengthens the Connection of β1 Integrin to Actin Cytoskeleton
In focal adhesions, the anchorage of integrins to actin filaments is crucial for the
proper mechanical strength of cell-matrix adhesion. To evaluate the roles of CD151 in the
connection of β1 integrins with actin cytoskeleton, we compared the amounts of β1
integrin in low concentration of Triton X-100-soluble (cytoplasmic) and -insoluble
(cytoskeleton associated) fractions, and found β1 integrin is more soluble in CD151 KD
cells than in MOCK cells. As shown in Figure 3-6, CD151 KD cells contain more
detergent-soluble and less detergent-insoluble β1 integrin than MOCK cells. This result
suggests loss of CD151 disturbs the association of β1 integrin with the
detergent-insoluble actin cytoskeletal matrix and supports the idea that CD151 promotes
the physical and functional linkage of β1 integrins with actin cytoskeleton for
strengthening of cell-matrix adhesion.

3.3.7 Reinforcement of Cell-matrix Adhesion Partially Rescues the Defective
Vascular Network Structures Formed by CD151-silenced Endothelial Cells
After observing that silencing of CD151 expression impairs cell adhesion onto
laminin 5 and cell traction on fibronectin and laminin 1, we then examined whether the
reinforcement of cell-matrix adhesion can overcome the instability of endothelial network
formed by CD151 KD cells during vascular morphogenesis. We added TS2/16 to the 3D
capillary formation experiment. As shown in Figure 3-7 and Table 3-1, integrin activation
by β1 integrin-activating mAb TS2/16 stabilized the network structure of CD151 KD
cells to the levels of untreated and control Ab-treated MOCK cells, suggesting that β1
integrin activation is sufficient to maintain the endothelial network in which CD151 is
silenced. Notably, TS2/16-stimulated MOCK cells form a more anastomosing and more
stabilized endothelial network, suggesting β1 integrin activation cannot fully rescue the
defects of CD151 silencing or optimize the network maintenance to the MOCK level.
These data also indicates that the impaired cell-matrix adhesion might not be the only
phenotypes in endothelial cells caused by loss of CD151.
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Figure 3-6. Loss of CD151 elevates detergent solubility of β1 integrin.
HMEC transductants were lysed with 0.05% Triton X-100 in HEPES buffer. Soluble and
insoluble fractions were obtained after ultracentrifugation, and were subjected to
SDS-PAGE. β1 integrin distributed in the fractions as well as whole cell lysates were then
detected by immunoblotting using TS2/16 mAb.
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Figure 3-7. TS2/16 partially rescues the defects in maintenance of capillary
structures in CD151-silenced endothelial cells.
HMEC transductants were incubated with 1 μg/ml β1 integrin activating mAb TS2/16 on
ice for 30 min, and were plated on Matrigel in the presence of TS2/16. The capillary-like
structures were photographed and quantified. An isotype-matched mAb (anti-human
CD71 antibody) serves as negative control. Bar = 250 μm.

Table 3-1. Quantitative results of Matrigel cable formation assay with TS2/16
treatment.
Antibodies Number of Circled Regions
per View of Field

Total Cable Length per View
of Field (μm)

MOCK
No mAb
34.2 ± 3.3
CD71 mAb 34.5 ± 3.5
TS2/16
74.2 ± 6.8

MOCK
13.0 ± 0.6
14.7 ± 2.9
25.5 ± 1.5

CD151 KD
6 ± 1.4
7.25 ± 4.8
29.5 ± 3.8
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CD151 KD
4.3 ± 1.0
5.6 ± 3.7
11.0 ± 1.4

3.3.8 CD151 Regulates CD44 Expression in Endothelial Cells
CD44 is encoded by an alternately spliced gene and contains tens of splicing
variants.172 To determine the effect of loss of CD151 in total CD44 mRNA expression,
we performed qRT-PCR used a pair of primers located at CD44 exons 1 and 2, which are
expressed by all CD44 splicing transcripts. As shown in Figure 3-8C, the total mRNA
level of CD44 was decreased, ~ 1.0 fold, in CD151-silencing HMECs compared to
non-silencing MOCK cells. Western blot and flow cytometry analysis confirmed both
total cellular and cell surface expression of CD44 protein were significantly
downregulated in CD151-silencing cells (Figure 3-8A and B). Hence we determined that
loss of CD151 downregulates gene expression of CD44. Because CD44 binds to
hyaluronan and connects with membrane-cytoskeleton linker ERM complex,173 CD151
likely regulates CD44-mediated but integrin-independent connection between matrix,
plasma membrane, and cytoskeleton.

3.4 Summary
In order to fully understand the mechanisms by which CD151 regulates vascular
morphogenesis and stability, we first investigated the roles of CD151 in endothelial cells
and cell motility. We found that CD151 does not regulate endothelial cell death and cell
motility and excluded the possibilities that CD151 promotes vascular stability by
regulating endothelial cell death and cell motility.
We next demonstrated that CD151 plays important roles in endothelial cell-matrix
adhesion. CD151 is needed for integrin α3β1-mediated initial establishment of cell
adhesion on laminin 5, and integrin α5β1- and α6β1-mediated cell adhesion strengthening
on fibronectin and laminin 1. We provide evidence that CD151 is not required for the
biophysical properties of α3 integrin- and/or CD9-containing TEM. We next
demonstrated that CD151 modulate the glycosylation of α3 integrin and regulate the
connection of β1 integrin with cytoskeleton. In addition, reinforcing cell-matrix adhesion
by activating β1 integrin activity could rescue the defects in maintenance of vascular
morphogenesis caused by loss of CD151 to some extents, evidencing that vascular
stability is at least partially dependent on CD151-mediated endothelial cell-matrix
adhesion. In addition, we found CD151 upregulates CD44 expression, suggesting a
regulatory role of CD151 in integrin-independent cell-matrix adhesion.
In short, the data above indicate that endothelial cell-matrix adhesiveness but not
cell death and cell motility become altered in the absence of CD151 and that vascular
instability caused by CD151 removal can be at least partially attributed to the impaired
endothelial cell-matrix adhesiveness.
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Figure 3-8. Loss of CD151 inhibits CD44 expression.
(A) Total cellular, (B) cell surface, and (C) mRNA levels of CD44 in HMEC transfectants
were determined by western blot, flow cytometry and qRT-PCR, respectively. *p < 0.01
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CHAPTER 4. CD151 REINFORCES ENDOTHELIAL CELL-CELL ADHESION

4.1 Introduction
Cell-cell adhesion is primarily mediated by cadherins, a family of
calcium-dependent single pass transmembrane molecules with differentially
tissue-specific expression pattern.120 At cell-cell junction sites, cadherins and α-, β-, and
γ-catenin, and p120ctn physically and functionally associate into adherens junction
complex to mediate homotypic intercellular interactions in the presence of calcium.120
Similar to integrins in focal adhesions, the cadherin/catenin junctional complex also
associates with vinculin or α-actinin to connect with cortical cytoskeleton.119,120 Within
endothelium, the roles of VE-cadherin-mediated AJs in vascular morphogenesis and
vascular barrier function have been well documented.12-14,174,175 In addition to
VE-cadherin, endothelial cells also express other calcium-independent cell-cell adhesion
molecules, such as occludin, claudins and JAM-1 as well as PECAM-1 and
ICAM-2.11,16,176
Because diminished endothelial cell-cell adhesion could lead to instability of
newly formed vasculature, CD151 may sustain neovascularization by reinforcing cell-cell
interactions. Hence, we used both in vitro and in vivo models to 1) assess the roles of
CD151 in modulating endothelial cell-cell adhesiveness and maintaining the structural
soundness of cell-cell contacts and 2) define the signaling steps by which CD151
stabilizes endothelial cell-cell adhesion.

4.2 Materials and Methods

4.2.1 Materials
Mouse anti-VE-cadherin mAb was from Santa Cruz Biotechnology (Santa Cruz,
CA). Mouse anti-α- and β-catenin mAbs were purchased from BD Biosciences (San Jose,
CA). Mouse anti-p120ctn was from Sigma-Aldrich (St. Louis, MO). Protein-A & -G
Sepharose beads were purchased from GE Healthcare (Piscataway, MA). Rho kinase
inhibitor Y27632 was purchased from Calbiochem (San Diego, CA). All other reagents
were described in previous chapters.
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4.2.2 Cell Aggregation Assay
To determine the roles of CD151 in calcium-dependent and -independent cell-cell
adhesion of endothelial cells, the hanging drop aggregation assay was performed as
described.177 A single cell suspension with 2 X 104 cells in 30 μl of complete cell culture
media or of calcium-free media was suspended as hanging drop on the lid of a 24-well
culture plate and allowed to aggregate overnight. Then the cells were subjected to shear
force by passing them 10 times through a 200 μl-filter pipette tip. Cells were
photographed, and 1) the number of single cells, and 2) the cells in clusters were counted
using ImageJ software. Then the ratios of aggregated cells to total cells were calculated,
and statistical analysis was performed. To evaluate the role of CD151 in crosstalking
RhoA signaling and endothelial cell-cell adhesion, we applied 10 μM Y27632 (a Rho
kinase inhibitor, which will be discussed in Chapter 5) to the cell suspension and
performd the hanging drop aggregation assay as described above.

4.2.3 Analysis of Cellular Distribution Adherens Junctional Complex
For the localization of VE-cadherin and β-catenin, HUVEC transductants were
plated on glass bottom cell culture dishes and cultured for 4 days to confluence. The cell
monolayer was then starved for 6 hours and processed for immunofluorescence in the
presence of 2 mM CaCl2 using VE-cadherin and β-catenin mAbs. Distribution of
VE-cadherin and β-catenin in CD151-silenced cells and MOCK cells was visualized
under a confocal fluorescent microscope.

4.2.4 Transmission Electron Microscopy (TEM)
For TEM, 12 week-old male mice were perfused with 10 ml of 0.1 M sodium
cacodylate buffer and fixed with 10 ml of 2.5% glutaraldehyde in the sodium cacodylate
buffer. The lung tissues were then excised and cut into approximately 1 X 1 X 1 mm3
cubes. The tissue samples were post-fixed in 1% osmium tetroxide, dehydrated in
dimethoxypropane, and embedded in epoxyresin LX-112 (Ladd Research, Williston, VT).
The sections were stained with 0.3% potassium ferrocyanide in 2.0% osmium tetroxide
and 4.0% uranyl acetate, and photographed under a transmission electron microscope.

4.2.5 Analysis of Protein Association of Adherens Junctional Complex
Protein associations within adherens junctional complex were analyzed by
co-immunoprecipitation (co-IP) as described previously with modifications178 using
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VE-cadherin and β-catenin mAbs. In brief, post-confluent HMEC cells were lysed on ice
for 15 min using co-IP lysis buffer (1% Brij 97, 0.2% Triton X-100, 50 mM HEPES, pH
7.2, 150 mM NaCl and 2 mM CaCl2) containing proteinase and phosphatase inhibitor
cocktail (10 μg/ml leupeptin, 10 μg/ml aprotinin, 2 mM sodium orthovanadate, 2 mM
PMSF, 2 mM sodium fluoride and 2 mM sodium pyrophosphate). Insoluble fraction was
removed by centrifugation at 13,000 rpm for 10 min. The amount of total protein in
supernatant was quantified using MicroBCA protein assay kit (Pierce, Rockford, IL) and
adjusted to equal. The lysates were pre-cleared with protein-A & -G Sepharose beads 3
times with each clearance of 1 hour at 4ºC and then incubated with specific antibody (1
μg Ab/500 μg total protein) at 4ºC for 1.5 hour to precipitate total cellular protein of
interest, followed by another 3 hour-incubation with protein-A & -G beads to bring down
the precipitates. The beads were collected and washed three times in lysis buffer. The
protein levels within the precipitates were then detected by immunoblotting.

4.2.6 Detergent Solubility Assay for VE-cadherin
The cytoskeletal association of VE-cadherin was analyzed by the detergent
solubility assay. In brief, post-confluent HMEC transductants were solubilized with
0.03% or 0.15% Triton X-100 in HEPES buffer containing 2 mM CaCl2. Then
detergent-soluble and -insoluble fractions were obtained as described in Section 3.2.7.
VE-cadherin distributed in the fractions as well as total cellular VE-cadherin was
detected by immunoblotting using VE-cadherin mAb.

4.3 Results

4.3.1 CD151 Strengthens Calcium-dependent Cell-cell Adhesion in Endothelial Cells
Endothelial cell-cell adhesion is critical for blood vessel formation and stability.
Since CD151 promotes epithelial cell-cell adhesion,85,116,117 we predict that
CD151-regulated endothelial cell-cell adhesion plays a role in CD151-dependent
vasculature stability. Hence, we compared endothelial cell-cell adhesion between
HMEC-MOCK and -CD151 KD cells using cell aggregation assay, a standard approach
to quantify cell-cell adhesion, in the presence and absence of calcium. We observed that
the loss of CD151 expression compromised calcium-dependent endothelial cell-cell
adhesion (Figure 4-1). In the presence of calcium, approximately two-thirds of
HMEC-MOCK cells (66.1% of total) were aggregated in the hanging drops of cell
suspension after the sheer force treatment. In contrast, a significantly less aggregation
(41% of total) was observed in CD151 KD cells. This result suggests CD151 strengthens
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Figure 4-1. Loss of CD151 impairs endothelial cell-cell adhesiveness.
2 X 104 cells were seeded into 30-μl hanging drop cultures in absence or presence of Ca2+
and/or Rho kinase inhibitor Y27632 (10 μM), which was used to determine the role of
CD151 in crosstalking RhoA signaling and cell-cell adhesion in endothelial cells, to
aggregate at 37ºC overnight. After trituration by passing the cell cluster 10 times through
a 200-μl filter pipette tip, cell cluster was photographed, and the degree of dissociation of
the aggregates was quantified using ImageJ analysis. Presented are representative images
of cell aggregation in the presence of Ca2+ without Y27632 (left panel, bar = 100 μm) and
the quantitative results (right panel). * p < 0.01.
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calcium-dependent cell-cell adhesion in endothelial cells.

4.3.2 CD151 Stabilizes VE-cadherin-mediated Adherens Junctions
The calcium-dependent cell-cell adhesion, i.e. adherens junctions, is mediated by
VE-cadherin and its associated catenins.120 In endothelial cells, CD151 is colocalized
with VE-cadherin at cell-cell contacts.80 Since VE-cadherin is essential for vascular
morphogenesis12-15 and barrier function,10,11,14 we next determined whether CD151
promotes endothelial cell-cell adhesion by stabilizing adherens junctions. As shown in
Figure 4-2, VE-cadherin and β-catenin were uniformly and continuously localized at
cell-cell contacts in HUVEC-MOCK monolayer, indicating the structural soundness of
endothelial adherens junctions. In HUVEC-CD151 KD cells, VE-cadherin and β-catenin
distribution was irregular and discontinuous at the cell-cell contacts and also found in
cytoplasma due to the loss of structural integrity in endothelial adherens junction. These
results suggest CD151 plays important roles in organization of AJs, thereby providing a
mechanism by which CD151 regulates to vascular stability.
To validate the in vitro observation, we examined the ultrastructure of pulmonary
endothelium, which are identified by the existence of red blood cells within blood
vessels, in CD151-null mice using TEM, a well-established technology to investigate
cell-cell junctions. In transmission electron micrographs, endothelial cell-cell adhesion,
particularly adherens junctions, is visible as narrow bands of electron-dense material
flanking the adjacent cells.179 As shown in Figure 4-3, the WT mouse lung tissue shows
nicely organized cell-cell junction structure in endothelium, as indicated by the
continuous and closely contacted electron-dense material between endothelial cells. In
contrast, many endothelial cell junctions become loose, and/or less electronically dense in
CD151-null mice under electron microscopy. Two adjacent plasma membranes in
endothelial cell junctions tend to dissociate from each other and form open gaps between
them when CD151 is ablated. This phenotype supports the decreased cell-cell adhesion
and increased permeability as observed above.

4.3.3 CD151 Is Not Required for the Assembly of Adherens Junctional Complexes in
Endothelial Cells
It was reported that integrin α3β1 and CD151 enhance cell-cell adhesion by
stabilizing cadherin-catenin complex in epithelial cells.116 To explore the in-depth
mechanism by which CD151 strengthens endothelial cell-cell junctions, we further
examined whether CD151 enhances cell-cell adhesion by stabilizing VE-cadherin
junctional complex and/or the connection of this complex to actin cytoskeleton. As
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Figure 4-2. Adherens junctional complexes are mis-localized in CD151-silenced
endothelial cell monolayer.
HUVEC transductants were cultured for 4 days to confluence. After 6-hour starvation,
HUVEC monolayers were fixed, permeablized and stained with specific antibodies. Then
the distributions of VE-cadherin and β-catenin in the monolayers were visualized under a
confocal microscope. Bar = 10 μm.

Figure 4-3. Abnormal endothelial cell-cell adhesion in lung vessels of CD151 KO
mice as seen in electron micrographs.
CD151 KO and littermate WT mice were perfused and fixed with 2.5% glutaraldehyde.
Then mouse lung tissues were excised and processed for TEM. Bar = 100 nm.
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revealed in co-immunoprecipitation, the levels of α-, β-catenin and p120ctn associated
with VE-cadherin and the levels of VE-cadherin, α-catenin and p120ctn associated with
β-catenin remained unchanged in HMEC-MOCK and -CD151 KD cells (Figure 4-4),
suggesting that CD151 is not required for and also probably does not modulate the
assembly of VE-cadherin junctional complex.

4.3.4 CD151 Reinforces the Cytoskeletal Connection of VE-cadherin
As revealed in the detergent solubility assay (Figure 4-5), more VE-cadherin was
solubilized by low concentration (0.15% or 0.03%) of Triton X-100 and found in the
soluble fractions from CD151 KD cells than those from MOCK cells, while the levels of
total cellular VE-cadherin remained the same in both MOCK and CD151 KD cells,
suggesting loss of CD151 elevates endothelial cellular solubility. The high solubility
indicates that loss of CD151 resulted in disconnection between VE-cadherin and the
detergent-insoluble actin cytoskeleton matrix. Thus we demonstrated that CD151
regulates endothelial adherens junctions through enforcing the anchorage of actin
filament to the junctional complex.

4.3.5 CD151 Regulates VE-cadherin-independent Cell-cell Adhesiveness in
Endothelial Cells
Finally, from cell aggregation analysis (Figure 4-1), we observed that CD151
silencing markedly reduced endothelial cell-cell adhesion (MOCK 47% vs. CD151 KD
30.8%) even in calcium-depleted medium, strongly suggesting that CD151 also modulate
the cell-cell adhesion mediated by calcium-independent, non-cadherin adhesion
molecules, such as PECAM-1 and ICAM-2, in endothelial cells.

4.4 Summary
In this chapter, we focus on the roles of CD151 in endothelial cell-cell adhesion.
We observed loss of CD151 attenuates endothelial cell-cell adhesiveness. This is in
particular applied to adherens junctions since CD151 silencing disturbs the enriched
distribution VE-cadherin and β-catenin at cell-cell contact sites. Furthermore, CD151 is
not required for the assembly of the junctional complex but rather important for the
anchorage between AJ complex and cortical cytoskeleton.
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Figure 4-4. The protein association in adherens junctional complex is not affected by
loss of CD151.
HMEC-MOCK or -CD151 cells were lysed in co-IP buffer. Then the indicated proteins
were immunoprecipitated, followed by immunoblotting with specific antibodies.
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Figure 4-5. Detergent solubility assay of VE-cadherin.
HMEC-MOCK or -CD151 KD cells were solubilized with 0.03% or 0.15% Triton X-100
in HEPES. After ultracentrifugation, supernatants were used as soluble fractions, and
pellets were solubilized in 1 Х SDS sample buffer and used as insoluble fractions. The
fractions were then subjected to SDS-PAGE, followed by immunoblotting with
anti-VE-cadherin mAb. Total cellular VE-cadherin was from 1 Х SDS sample buffer
extracted whole cell lysates.
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CHAPTER 5. CD151 MODULATES SMALL GTPASES RAC1 AND RHOA
SIGNALINGS AND RESTRAINS ENDOTHELIAL CYTOSKELTAL TENSION

5.1 Introduction
Rho GTPases are a family of GTP-binding proteins, of which RhoA, Rac1 and
Cdc42 are best understood. Active RhoA activates its downstream signal molecule Rho
kinase and promotes serine- and threonine-phoralyation of myosin light chain (MLC)
which in turn induces stress fiber formation and cytoskeletal tension (Figure 5-1).17
Previous studies have demonstrated that, RhoA-dependent cytoskeletal organization is
crucial in the maintenance of endothelium stability.19-21 Excess RhoA activity disturbs the
barrier function of angiogenic vessels and selectively induces regression of vasculature,
whereas suppression of RhoA signaling promotes angiogenesis and vessel stability.19-21
Other small GTPases, such as Rac1, are also important in angiogenesis because
Rac1-dependent cytoskeleton reorganizations could largely promote endothelial cell-cell
junctions and maintain vascular barrier function.22,23 In addition, antagonism constantly
exists between Rac1 and RhoA signalings, as illustrated by Bar-Sagi pathway.180
Three classes of regulatory proteins are involved in direct regulation of small
GTPases activity by controlling the loading and hydrolysis of GTP: guanine nucleotide
exchange factors (GEFs), GTPase-activating proteins (GAPs) and the guanine nucleotide
dissociation inhibitor (GDIs), and each consists of tens of members with different
specificities to Rho family.181-183 Among these regulators, p190RhoGAP, which can be
avtivated by integrin signaling,184-186 and p115RhoGEF, which can be activated by
G-protein coupled receptors (GPCRs),187,188 are of particular importance in regulating
RhoA signaling (Figure 5-1). In addition, cyclic AMP (cAMP) directly or indirectly
controls small GTPase activites through protein kinase A (PKA)-mediated
phosphorylation. For example, PKA suppresses RhoA activities via direct
phosphorylation of RhoA,189,190 whereas Rac1 activity can be induced by PKA-mediated
phosphorylation/activation of Tiam1, a Rac1-specific GEF.191,192
Previous studies suggest that CD151 regulates Rho GTPase activities in tumor
cells.
We predict that vascular endothelial CD151 also regulates RhoA and Rac1
signalings. Therefore, we performed signal transduction studies to investigate the roles of
CD151 in RhoA and Rac1 activation and their upstream and downstream signaling
events. We also used the RhoA signaling inhibitors and retrovirus-based Rac1
overexpression system in the in vitro vascular morphogenesis assay to determine if
CD151 regulates vascular stability via RhoA and Rac1.
85,112,117
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Figure 5-1. A diagram showing RhoA and Rac1 signalings and the upstream signals.
Small GTPase RhoA and Rac1 are constantly antagonisic. RhoA, in its GTP-loaded
form, triggers the downstream signaling cascade including activation of Rho kinase and
phosphorylation of MLC, which in turn induces the assembly of actomyosin and
formation of contracile actin stress fibers. Whereas Rac1, in response to GF or integrin
signaling, activates PAK1 and leads to cortical actin meshwork and lamellipodia
formations. The establishment of cortical actin cytoskeleton promotes the assembly of
adherens junctional complexes, which recruit p190RhoGAP to the junctional sites and
subsequently suppress RhoA activity to maintain the connection of adherens junctional
complex with cortical actin filament. In addition, the antagonism between Rac1 and
RhoA signalings could be mediated by the signaling pathway involving release of ROS
and activations of eNOS and p190RhoGAP. The cAMP/PKA signaling pathway promotes
Rac1 activity and suppresss RhoA activity via phosphorylation, and thus provides
another mechanism to maintain the antagonism between Rac1 and RhoA signalings.
Other signals controlling RhoA activation also exist, such as the RhoA-specific
p115RhoGEF. cAMP, cyclic adenosine monophosphate; eNOS, endothelial nitric oxide
synthase; GAP, GTPase-activating protein; GEF, guanine nucleotide exchange factor;
GF, growth factor; GPCR, G-protein coupled receptor; MLC, myosin light chain;
PAK1, p21-activating kinase 1; PKA, protein kinase A; Robo, Roundabout; ROS,
reactive oxygen species.
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5.2 Materials and Methods

5.2.1 Materials
Rabbit anti-diphospho-myosin light chain (2P-MLC) II, anti-MLC II and
anti-p115RhoGEF polyclonal antibodies were obtained from Cell Signaling Technology
(Beverly, MA). Mouse anti-phospho-tyrosine (PY99) monoclonal antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-RhoA, anti-Rac1 and
anti-p190RhoGAP mAbs were purchased from BD Biosciences (San Jose, CA).
Glutathione-conjugated Sepharose 4B beads were purchased from GE Healthcare
(Piscataway, MA). Cell-permeable C3 transferase was purchased from Cytoskeleton
Corp. (Denver, CO). Rho kinase inhibitor Y27632 and Adenosine-8-bromo-3', 5'- cyclic
monophosphate (8-Br-cAMP) were purchased from Calbiochem (San Diego, CA).
Blebbistatin and ML7 were obtained from TRC (Toronto, Canada). All other reagents
were described in Chapters 2-4.

5.2.2 Analysis of Stress Fiber Formation
Stress fiber formation in HMEC transductants was detected by staining with
Alexa Fluro 594-conjugated phalloidin.

5.2.3 Glutathione S-transferase (GST) Pull-down Assays
The activation of RhoA, Rac1, p115RhoGEF or p190RhoGAP was detected by the
GST pull-down method using recombinant proteins: GST-Rhotekin Rho-binding domain
(GST-TRBD) which binds to RhoAGTP, GST-p21-activated kinase 1 (PAK1)
Rac1-binding domain (GST-PRBD) which binds to Rac1GTP, GST-RhoA
nucleotide-empty mutant RhoA (G17A) which binds to active p115RhoGEF, and
GST-RhoA constitutively active mutant RhoA (Q63L) which binds to active p190RhoGAP
as described previously.28,193 To produce GST fusion proteins, 10 μl E. coli transformed
by GST fusion constructs was added into 3 ml LB media containing 100 µg/ml ampicillin
and grew for 3 hour at 37ºC. Then the bacterial media was pipetted into 250 ml
LB/ampicillin and grew at 37ºC with agitation until the absorbance at 600 nm was 1.0.
Then IPTG was added at 0.1 mM final concentration into bacteria culture followed by
further 2 hour-incubation at 28ºC to induce fusion protein expression. Bacteria culture
was spilt into 50 ml aliquots and centrifuged for 30 min at 3,000 rpm. To generate fusion
protein-bound beads, pellet bacteria from 50 ml bacteria culture was resuspended in 2 ml
PBS and lysed by adding 80 μl of 100 mg/ml lysozyme, 20 μl of 1 M DTT and 40 μl of
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0.1 M proteinase inhibitor PMSF for 15 min on ice. Then 225 μl of 10% Triton X-100, 50
μl of 1 mg/ml DNase and 25 μl of 1 M MgCl2 were added into bacteria lysate. After
another 15 min-incubation on ice, the bacteria debris was removed by centrifugation at
10,000 rpm for 10 min at 4ºC. Supernant containing GST fusion protein was incubated
with 250 μl glutathione-sepharose 4B beads for 30 min at 4ºC. After 3 washes, the fusion
protein-bound beads were then resuspended in PBS containing 10 mM DTT to a 50%
slurry, aliquoted and stored at -80oC until needed. Prior to pulldown experiment, HMECs
(2.5 X 106 cells) were seeded in 10-cm cell culture dish precoated with diluted Matrigel,
and cultured at 37ºC overnight. On the second day, cells were lysed in 1.5 ml modified
RIPA buffer (50 mM Tris, pH7.2, 500 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 10 mM MgCl2) containing protease and phosphatase inhibitor
cocktail. Insoluble fraction was removed by centrifugation, and supernatant was
incubated with 30 μl of 50% GST fusion protein-bound bead slurry for 30 min at 4ºC.
Then the beads were washed by washing buffer (50 mM Tris pH7.2, 1% Triton X-100,
150 mM NaCl, 10 mM MgCl2) 3 times. The precipitated proteins were eluted by
Laemmli buffer and subjected to SDS-PAGE and immunoblotting using appropriate
mAbs.

5.2.4 Detection of Rho Kinase Activity
The Rho kinase activity was measured in ELISA using a commercial available
Rho kinase activity Kit (MBL International, Woburn, MA) according to the
manufacture’s instruction. In brief, HMEC cell lysates were prepared as in the pulldown
experiments. 10 μl cell lysate diluted with 90 μl kinase reaction buffer (ATP plus), in
triplicate, was added into 96-well plate precoated with a substrate corresponding to
recombinant the C-terminus of MBS (myosin-binding subunit of myosin phosphatase), in
which a threonine residue (Thr696) can be phosphorylated by Rho kinase. After 30-min
incubation at 30ºC to allow phosphorylation at the threonine-696, the wells were washed
and incubated with 100 μl detection solution containing HRP-conjugated AF20, an
anti-phospho-MBS threonine-696 specific antibody, to bind the phosphorylated substrate
with AF20. The bound HRP-conjugated AF20 catalyzed the conversion of the
chromogenic substrate tetra-methlybenzidine (TMB) from a colorless solution to a blue
solution, which was then converted to yellow after the addition of 100 μl of 0.5 N H2SO4
for stopping the reaction. The yellow color was then quantified by spectrophometry at the
wavelength of 450 nm. Purified recombinant Rho kinase-II positive control (1 mU/μl
stock) at various doses was used to calculate the enzyme catalytic domain (standard
curve). The relative enzymatic activities from different HMEC transfectants were
calculated using the standard curve, and compared statistically. In addition, the activity of
purified recombinant Rho kinase-II (10 mU/reaction) in the presence of 10 μM Y27632
were measured by this assay in order to determine the inhibitory effect of Y27632 on Rho
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kinase.

5.2.5 Analysis of MLC Phosphorylation
HMEC cell lysates were prepared as in the GST pull-down assay and processed
for immunoblotting to determine the levels of dual-phosphorylated MLC (2P-MLC) as
well as total MLC using the specific antibodies against 2P-MLC and MLC.

5.2.6 RhoA Signaling Inhibitor Treatment
HMEC transfectants or MLECs were plated on Matrigel as described in Section
2.2.6. 3 hours later, C3 transferase (2.5 μg/ml), Y27632 (10 μM) or Blebbistatin (5 μM),
specific inhibitor for RhoA, Rho kinase, and myosin II, respectively, was applied to cells.
The cable network structures were monitored 18 hour later. ML7, a specific inhibitor
against myosin light chain kinase (MLCK), served as negative control.

5.2.7 Analysis of Upstream Signaling of RhoA and Rac1
The tyrosine phosphorylation of p190RhoGAP was analyzed by IP. Total cellular
p190RhoGAP in HMEC transductants was immunoprecipitated with a p190RhoGAP mAb,
and subjected to SDS-PAGE and immunoblotting. The level of tyrosine phosphorylation
in the precipitated p190RhoGAP was detected by an anti-phospho-tyrosine mAb (PY99).
After stripping, total input of p190RhoGAP was then determined by p190RhoGAP mAb.
For fast-cycling mutant Rac1 (F28L) retroviral transduction, HMEC-MOCK or
-CD151 KD cells were cultured at 37ºC overnight and then incubated with GFP-Rac1
F28L virus in the presence of 5 μg/ml polybrene. On the second day, virus-containing
medium was replaced by fresh medium. Rac1 F28L expressing cells were determined by
flow cytometry and then enriched by GFP sorting. The Rac1 F28L-expressing cells were
then used for the 3D capillary formation on Matrigel as described in Section 2.2.6.
Various concentrations of 8-Br-cAMP were also used in the 3D capillary formation to
explore the upstream signaling pathway.
The expression levels of Slit2 in HMEC transductants were measured by
qRT-PCR as described for CD44 in Section 3.2.9. A 73 nt amplicon of human Slit2 gene
was obtained from qRT-PCR using the primer pair “GTGTTCGTGCCAGCTATGAD”
and “CCATCATTGATTGTCTCCACAC” for the forward and reverse primer,
respectively. And the mRNA expression levels of Slits were calculated, normalized by
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setting the relative Slit2 mRNA levels in MOCK cells as 1, and compared.

5.3 Results

5.3.1 CD151 Restrains Stress Fiber Formation in Endothelial Cells
The altered endothelial cell adhesiveness drove us to analyze the effect of CD151
removal on cytoskeleton organization. CD151-silenced endothelial cells typically exhibit
fibroblast-like morphology with long and thick F-actin bundles which transverse from
one end to the other end of a cell (Figure 5-2), indicating that CD151 expression is
needed for inhibiting robust formation of stress fibers. In contrast, CD151-expressing
endothelial cells often display relatively thin, short, and intersected F-actin filaments
which frequently form cortical meshwork, implying the existence of lamellipodia (Figure
5-2).

5.3.2 CD151 Balances the Activations of Rac1 and RhoA Signalings
RhoA-Rho kinase-myosin signaling cascade is primarily responsible for stress
fiber formation and cell retraction,181 while the activation of Rac1 leads to the formation
of cortical actin meshwork and lamellipodia. Based on the results from time-lapse
microscopy and IF, we also predict that CD151 silencing enhances cell tension or
contractility. By comparing the levels of active RhoA (GTP-bound RhoA) between
HMEC-CD151 KD and -MOCK cells, we found that loss of CD151 results in significant
upregulation of RhoA activity (Figure 5-3A, left panel). The quantitative data (Figure
5-3A, right panel) suggest that the ratio of active RhoA to total RhoA in CD151 KD cells
is higher (~ 1 fold) than that in MOCK cells. This result underlines that CD151 is needed
for restraining RhoA activity in endothelial cells. To substantiate this observation, we
also measured and compared the activities of RhoA downstream such as Rho kinase
activity and phosphorylation levels of MLC in HMEC-MOCK and -CD151 KD
transfectants. Rho kinase activity is approximately 1-fold higher in CD151 KD cells than
MOCK cells (Figure 5-3B), in accordance with elevated RhoA activation. The
dual-phosphorylation of MLC at Thr18 and Ser19 (2P-MLC), which is the active form of
MLC and essential for assembly of actomyosin and stress fiber formation, was also
markedly increased (Figure 5-3C).
In contrast, the level of active, GTP-loaded Rac1 is reduced in HMEC-CD151 KD
cells compared to -MOCK cells (Figure 5-3D). Hence, CD151 silencing deregulates the
activities of Rho small GTPases and leads to the upregulation of RhoA and
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Figure 5-2. Loss of CD151 expression results in increased stress fiber formation.
HMEC transductants were stained with Alex Fluor 488-conjugated phalloidin after
spreading overnight. F-actin staining was then visualized with a confocal microscope.
Bar = 10 μm.
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Figure 5-3. Loss of CD151 expression results in upregulation of RhoA-Rho
kinase-myosin signaling and downregulation of Rac1 signaling.
(A) HMEC transductants were seeded in diluted Matrigel-coated dish and cultured
overnight. Cell lysates were incubated with GST-TRBD beads to pull down GTP-bound
RhoA. RhoA levels from the pulled down precipitates and in whole cell lysates were then
determined by SDS-PAGE and immunoblotting using anti-human Rho mAb. The blot
(left panel) is representative of four independent experiments. RhoAGTP/total RhoA ratio
(right panel) was calculated from the density of the blots and normalized to MOCK
group. * p < 0.01. (B) Cellular Rho kinase enzymatic activities were measured using a
commercially available immunoassay kit. Data from 4 independent experiments were
normalized to MOCK group. * p < 0.01. (C) HMEC cells were seeded as in RhoA
pulldown assay and lysed in RIPA buffer for 20 min at 4ºC. After centrifugation, cell
lysates were obtained and processed for SDS-PAGE and immunoblotting to detect total
MLC and 2P-MLC. (D) The GTP-bound Rac1 was precipitated from HMEC cell lysates
using GST-PRBD beads. Levels of Rac1GTP and total cellular Rac1 were determined by
immunoblotting using Rac1 mAb (left panel). Rac1GTP/total Rac1 ratio was then
calculated, normalized and compared between MOCK and CD151 KD cells (right panel).
* p < 0.01.
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downregulation of Rac1 signaling, likely reflecting the antagonism between RhoA and
Rac1 described earlier.180

5.3.3 RhoA Signaling Inhibitors Restore the Unstabilization of Vascular Network
Structures Caused by Loss of CD151
The RhoA-Rho kinase-myosin signaling can be selectively blocked by the
inhibitors such as C3 transferase, Y27632, and Blebbistatin, specific inhibitor for RhoA,
Rho kinase, and myosin light chain assembly, respectively.181,194,195 To determine if
RhoA signaling is needed for CD151-dependent maintenance of vascular stability, we
applied these specific inhibitors in the in vitro vascular cable network formation assay on
Matrigel. As shown in Figure 5-4A, all RhoA signaling inhibitors stabilized the
endothelial network structures formed by CD151 KD cells, and MOCK and CD151 KD
endothelial cells exhibited similar levels of morphogenesis. Consistently, Rho kinase
inhibitor Y27632 also overrode the difference in vascular morphogenesis of primary lung
endothelial cells isolated from WT and CD151-null mice (Figure 5-4B). These results
underscore that sustained RhoA signaling is necessary for CD151-mediated maintenance
of vascular stability. As negative control, ML-7, a specific inhibitor of myosin light chain
kinase (MLCK), exerted no significant influence on the formation and maintenance of
endothelial networks (Figure 5-4A). Since MLCK is exclusively involved in
Ca2+-induced muscle cell contraction, ML-7 should not affect RhoA signaling in
endothelial cells as predicted. In addition, to validate the rescuing effect, we show that
Y27632 at (10 μM) is capable of inhibiting the activity of purified Rho kinase II to a
significant low level (Figure 5-5), and thus confirmed the biochemical property of
Y27632 to inhibit Rho kinase activity in our system.
In addition, the impaired cell-cell adhesiveness of CD151-silenced endothelial
cells was also reversed by Y27632 in the presence as well as absence of Ca2+ (Figure
4-1), indicating that RhoA signaling is essential for CD151-reinforced endothelial
cell-cell adhesiveness.

5.3.4 Elevation in Intracellular cAMP but Not Active Rac1 Can Rescue Unstabilized
Vascular Network Structures Formed in CD151 KD Cells
As a key signaling molecule important in many biological processes, cAMP has a
well-established protective effect on endothelial barrier properties.196-200 CAMP, through
activation of PKA-dependent phosphorylation on Rho GTPases, could enhance vascular
barrier by inducing Rac1-mediated cytoskeletal reorganization and/or inhibiting RhoA
activation.196-200 To investigate the role of cAMP signaling in CD151-mediated
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Figure 5-4. Rho signaling inhibitors restore the defective vascular network
structures caused by loss of CD151.
For the in vitro cable network formation assay, various inhibitors (C3 transferase, 2.5
μg/ml; Y27632, 10 μM; Blebbistatin, 5 μM; and ML-7, 5 μM) were added at 4 hour after
HMEC transductants (A) or MLECs (B) were plated on Matrigel. The capillary-like
structures were photographed 14 hour later. Bar = 250 μm.
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Figure 5-5. The inhibition effect of Y27632 on Rho kinase activity.
The activity of purified Rho kinase II (10 mU) was determined in the presence and
absence of 10 μM Y27632 using the Rho kinase activity kit.
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stabilization of vascular network structures, we elevated intracellular cAMP by applying
a long-acting cAMP derivative, 8-Br-cAMP, to the HMEC tranductants. As shown in
Figure 5-6A, elevation in intracellular cAMP by 8-Br-cAMP (500 μM) could completely
rescue the unstabilized vascular structures formed by CD151 KD cells. Moreover, the
rescuing effect by the cAMP derivative exhibits a dose-dependent manner (Figure 5-6B),
suggesting a close functional relationship between cAMP and CD151 in vascular
stabilization. These results also provide evidence that cAMP signaling might be the
upstream signal of CD151-mediated restraint on RhoA in a manner dependent or
independent on Rac1.
cAMP/PKA signaling could regulate vascular stability through Rac1-dependent
RhoA inhibition. To further understand the role of Rac1 signaling in CD151-mediated
vascular stabilization, we next upregulated Rac1 activity in endothelial cells by using
Rac1 F28L mutant, which fast cycles between GTP- and GDP-loaded forms.201
Overexpression of Rac1 F28L mutant in CD151 KD endothelial cells cannot rescue the
instability of vascular network structures (Figure 5-6C), indicating Rac1 signaling is not
required for CD151-mediated vascular stabilization. Together, our results suggest that
CD151 regulates vascular stability through RhoA but not Rac1 and also indicate cAMP
signaling directly modulates RhoA activity by PKA-dependent protein phosphorylation.

5.3.5 CD151-mediated Restraint on RhoA Is Not Dependent on P190RhoGAP and
P115RhoGEF
As illustrated by Bar-Sagi pathway,180 antagonism constantly exists between Rac1
and RhoA signalings. It was reported that p190RhoGAP, a RhoA-specific GAP and major
regulator of RhoA, coordinates such antagonism by anchoring to adherens junctions.30
We next determined if CD151 confines RhoA activity in a p190RhoGAP-dependent
manner. Given the fact that active p190RhoGAP is phosphorylated at tyrosine residues, we
examined the tyrosine phosphorylation levels of p190RhoGAP in HMEC transfectants and
found that the level of tyrosine phosphorylated p190RhoGAP in CD151 KD cells is
comparable to that in MOCK cells (Figure 5-7A). Additionally, we performed a pulldown
assay using RhoA Q63L, a constitutively active RhoA mutant which selectively binds the
activated, RhoA-specific GAPs,27,202 to directly detect the level of active p190RhoGAP. As
shown in Figure 5-7B, the amount of p190RhoGAP coprecipitated with RhoA Q63L
remains unchanged in CD151 KD cells compared to MOCK cells. Collectively,
p190RhoGAP activation is not affected by CD151 silencing, and p190RhoGAP appears not
to be crucial for CD151-dependent restraint of RhoA signaling.
Another major upstream regulator for RhoA is p115RhoGEF, a specific guanine
nucleotide exchange factor for RhoA.203 We compared MOCK and CD151 KD
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Figure 5-6. Elevation in intracellular cAMP but not active Rac1 rescues the
defective vascular network structures caused by loss of CD151.
(A-B) 8-Br-cAMP at various concentrations was applied in HMEC transductants for
cable network formation assay. The network structures were photographed at 18 h, and
the number of cable cord-enclosed regions was counted from the photographs. Presented
are (A) representative images of the cable network structures with treatment of 500 μM
8-Br-cAMP, and (B) quantitative data of the network structures in the presence of various
concentrations of 8-Br-cAMP. (C) Expressing a fast-cycling Rac1 (F28L) mutant cannot
rescue CD151-silencing derived vascular instability. Rac1 F28L with GFP fusion was
overexpressed in HMEC transductants by a retroviral construct. Cells were undergone
GFP sorting to separate GFP-Rac1 F28L positive and negative cells. Sorted cells were
then subjected to the cable network formation assay and photographed at 18 h. Bar = 250
μm.
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Figure 5-7. Upstream signaling studies.
(A-C) CD151 does not affect p190RhoGAP and p115RhoGEF activation. (A) Cellular
p190RhoGAP were IPed with anti-p190RhoGAP mAb, and the amount of phosphorylated
p190RhoGAP at tyrosine was determined by immunoblotting with anti phospho-tyrosine
mAb PY20. After stripping, total precipitated p190 was detected with anti-p190RhoGAP
mAb. (B-C) The active form of p190RhoGAP (B) or p115RhoGEF (C) was detected by GST
pull down using GST-fused constitutively active RhoA mutant (Q63L) and GST-fused
nucleotide-empty RhoA mutant (G17A), respectively. (D) Loss of CD151 upregulates
Slit2 expression. The levels of mRNA expression of Slit2 gene were determined by
qRT-PCR. * p < 0.01.
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endothelial cells for the levels of active p115RhoGEF using a GST fusion of RhoA G17A
mutant, an empty-nucleotide mutant that cannot bind to GTP&GDP and specifically
interacts active p115RhoGEF.202 As shown in Figure 5-7C, the amount of the RhoA
G17A-bound p115RhoGEF, which represents active pool of p115RhoGEF, in MOCK cells
was virtually the same as that in CD151 KD cells, indicating that p115RhoGEF is unlikely
to be the upstream signal in CD151-induced containment of RhoA signaling.

5.3.6 CD151 Downregulates Slit2 Expression
Although CD151 promotes Rac1 and Cdc42 signaling,74,85,112 the mechanism
remains unknown. Slit2 is the activating ligand of Roundabout proteins, which maintain
vascular integrity, and inhibits Rac1 and Cdc42.204,205 We assessed the mRNA levels of
Slit2 in HMEC transfectants using qRT-PCR and found that the transcript level of Slit2 in
CD151 KD cells was increased ~ 1 fold compared to that in MOCK cells (Figure 5-7D).
Upon CD151 silencing, the upregulated Slit2 gene expression correlates well with the
downregulated Rac1 signaling.

5.4 Summary
We have demonstrated the role of CD151 in RhoA signaling-mediated
cytoskeletal tension and its contribution to vascular stability. CD151 could prevent stress
fiber formation by inhibiting RhoA-Rho kinase-MLC signaling, leading to lower cell
contractility and tension. Specific inhibitors of RhoA signaling could completely rescue
the phenotypic changes in vascular stability caused by loss of CD151. These results
suggest that CD151 contributes to vascular stability via its negative regulation in RhoA
signaling-mediated stress fiber formation and cellular contractility. In addition, RhoA
signaling inhibitor restores endothelial cell-cell adhesiveness, revealing that CD151 may
regulate cell-cell adhesion through a RhoA-dependent mechanism.
We next observed downregulation in Rac1 activity and upregulation in gene
expression of Slit2 in CD151-silenced HMECs. Moreover, we found elevation in
intracellular cAMP could rescue the unstabilized vascular network structures in CD151
endothelial cells. We next excluded the possibility that Rac1 is involved in
CD151-mediated stabilization of vasculature, since elevating active Rac1 levels by a
fast-cycling Rac1 mutant cannot rescue the deficient vascular network structures. We also
provided evidence that the regulation of CD151 on RhoA signaling is p190RhoGAP- and
p115RhoGEF-independent. Together, cAMP signaling but not Rac1, p190RhoGAP or
p115RhoGEF is the upstream signals of CD151-dependent restraint of RhoA activation.
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CHAPTER 6. DISCUSSION

6.1 Introduction
It has been well established that CD151 is a tumor metastasis promoter. Thus far,
it is relatively clear that, through the stable physical association with and functional
connection to laminin-binding integrins, CD151 promotes tumor progression by
upregulating cell motility, cell adhesion, proteolytic activity of MMPs, and
metastasis-related signaling pathways. CD151 was also shown to promote pathological
angiogenesis.74 How CD151 regulates pathological angiogenesis, however, remains
largely unknown.
In the present study, we aimed to define the mechanisms by which CD151
regulates vascular morphogenesis, an essential process involved in vasculogenesis and
angiogenesis. In Chapter 2, we characterized a critical role of CD151 in maintaining
vascular stability both in vitro and in vivo. In Chapters 3 to 5, we examined the
molecular, cellular, and signaling mechanisms by which CD151 stabilizes vascular
stability. Our current understanding favors a novel model in which CD151 coordinates
multiple biological processes of endothelial cells including cell-matrix adhesion, cell-cell
adhesion, and cytoskeletal tension by strengthening the membrane connections of actin
cytoskeleton (Figure 6-1). In this chapter, we will discuss this model in detail and define
its biological significance.

6.2 Tetraspanin CD151 Promotes Vascular Stability
Tetraspanin CD151 is widely expressed in epithelial, smooth muscle, and
endothelial cells as well as platelets and megakaryocytes.51,54,68 The expression level of
CD151 is particularly high in endothelial cells and platelets. Lines of evidence support
that CD151 plays important roles in angiogenesis under selective pathologic conditions in
vitro and in vivo.73,74,76,89 In this study, we found that loss of CD151 expression disrupts
vascular stability and results in aberrant vascular permeability. In the absence of CD151,
endothelial cells can initiate the formation of capillary network structures on Matrigel but
cannot sustain the vascular structures in vitro (Figure 2-4 and supplementary videos).
Consistently, ablation of CD151 in mouse causes elevated microvascular permeability
under inflammatory condition (Figure 2-5).
Vascular morphogenesis is the process involving the assembly of endothelial cells
into capillary structure during vasculogenesis and angiogenesis.1 During vascular
morphogenesis, numerous factors regulate endothelial cell proliferation, migration, and
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Endothelial cells

Figure 6-1. A working model for CD151 in stabilizing vascular structures.
(A) After the endothelial network structures are formed, CD151 could balance endothelial
cell-matrix adhesion, cell-cell adhesion and cytoskeletal traction and thus stailizes the
vasculatures. (B) In the absence of CD151, the endothelial network structures can be
formed but not maintained properly. The CD151-negative vasculature exhibits weakened
endothelial cell-matrix and cell-cell adhesions and elevated cellular contractility. CD151
might promote cell adhesion through strengthening the connection of actin cytoskeleton
to the cell adhesive machinery.
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adhesion, vessel wall assembly, and endothelium structural integrity and stability.1,14,206
Therefore, vascular morphogenesis and the stabilization of newly formed vasculatures
depend on 1) proper migration and proliferation of endothelial cells and 2) the
coordination of cell-cell adhesion, cell-matrix adhesion, and basement membrane
assembly.207
As demonstrated in live imaging, endothelial cells underwent cell attachment and
spreading, active migration and retraction, and dynamic interaction among cells and with
surrounding matrix during vascular morphogenesis. Since loss of CD151 disrupts the
maintenance of newly formed vascular structure after vascular morphogenesis, CD151 is
likely involved in regulating any of cellular processes described above. Our data suggest
that loss of CD151 does not markedly affect endothelial cell death and motility but results
in impaired cell-matrix adhesiveness, upregulation of RhoA signaling, and aberrant
endothelial adherens junctions (diminished cell-cell adhesiveness). It can be envisioned
that, CD151 balances cell-matrix adhesiveness, cell-cell adhesion, and cell contraction in
endothelium during blood vessel formation and therefore stabilizes the newly formed
vasculature. In the absence of CD151, endothelial cells tend to fall off from the
underlying matrix due to the impaired cell-matrix interaction, increased intrinsic tension
from upregulated RhoA signaling, and diminished cell-cell junctions of the newly formed
vasculature. Consequently, CD151-negatively vessels are prone to be unstable and
disrupted.

6.3 CD151 Regulates Multiple Endothelial Cell Events
CD151 forms stable association with laminin-binding integrins α3β1, α6β1, α6β4,
and α7β1.61,71,76 It has been well established that CD151, together with the integrins, is
involved in a variety of cellular processes including neurite outgrowth and platelet
aggregation as well as cell morphogenesis, cell-matrix adhesion strengthening, cell-cell
adhesion, and cell migration in epithelial and tumor cells.72,76,79,84,85,91 The engineering of
endothelial cells without or with diminished CD151 expression has permitted us to
investigate the roles of CD151 in endothelial physiology and pathophysiology. Using this
experimental system, we not only observed similar mechanism by which CD151
regulates endothelial cell behaviors but also elaborated the general understanding of
CD151 biological functions and vascular stability.

6.3.1 CD151 Does Not Affect Endothelial Cell Death and Cell Motility
CD151 has not been implicated to modulate cell survival and proliferation or
cause apoptosis or necrosis. Indeed, in the cell death assay, we found loss of CD151 does
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not affect endothelial cell viability on Matrigel for as long as 54 hour (Figure 3-1). In
addition, earlier observation has shown CD151 ablation has no impact on endothelial cell
proliferation.74 Thus, we can exclude the possibility that CD151 promotes vascular
stability by regulating cell death and proliferation.
Previous studies showed that CD151 enhances tumor invasion and metastasis
through regulating integrin-dependent cell migration.72,79,101,102 However, we found that
CD151 silencing does not significantly alter the hapotactic and chemotactic cell
movement in Transwell cell migration assay as well as random cell movement in wound
healing assay of microvascular endothelial cells (Figure 3-2). In contrast to a myriad of
evidence supporting a regulatory role of CD151 in tumor cell motility, no effect of
CD151 on endothelial cell motility suggests that CD151-regulated machinery of cell
migration is distinct from cells to cells or CD151-regulated signaling step for cell
migration is tissue specific.

6.3.2 CD151 Optimizes Endothelial Cell-matrix Adhesion
Cellular interactions with extracellular matrix are essential in angiogenesis. The
formation of vasculatures requires the adhesion of endothelial cells to basement
membranes.4,207 CD151-associated laminin-binding integrins α3β1, α6β1, and α6β4 play
pivotal roles in cell-basement membrane adhesion,140,208,209 and CD151 is highly involved
in regulating cell-matrix adhesion in epithelial or tumor cells.79,81-83,91 We demonstrated
in this study that CD151 also strengthens integrin-dependent cell-matrix adhesion in
endothelial cells.
First, the reduction or loss of CD151 expression impairs the adhesion of
endothelial cells onto laminin 5, the ligand of integrins α3β1 and α6β4, in the short-term
cell-matrix protein adhesion assay (Figure 3-3A), indicating that CD151 is required for
the optimal cell adhesion dependent on integrins α3β1 and α6β4. However, CD151 is not
needed for the total cell surface expression levels or basal surface distribution of integrin
α3β1 as well as tetraspanin CD9 in endothelial cells (Table 2-1 and Figure 3-4). A recent
study demonstrated that CD151 determines the glycosylation of α3 integrin.62 We
observed consistant results, as reported in that study, which suggests that loss of CD151
attenuates the glycosylation of α3 integrin subunit in endothelial cells (Figure 3-5). It
may be the mechanism by which CD151 strengthens integrin α3β1-mediated cell-matrix
adhesion. In addition, we also observed CD151 strengthens integrins α6β1 and
α5β1-dependent cell adhesion on fibronectin and laminin 1, respectively (Figure 3-3B).
Moreover we found CD151 reinforces the connection of β1 integrins to actin
cytoskeleton (Figure 3-6). Thus, CD151 likely potentiates the adhesion ability of β1
integrins by enhancing the connection of actin cytoskeleton to these integrins.
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Furthermore, CD151 upregulates the expression levels of cell-matrix protein CD44
(Figures 3-3 and 3-8), underlining that CD151 as a global regulator of both
integrin-dependent and -independent cell-matrix adhesions in endothelium. Further
studies should be directed to identify 1) the protein association of β1 integrin subunit
with actin network and 2) the mechanism by which CD151 upregulates other cell-matrix
adhesion proteins, to depict a complete picture of CD151-mediated strengthening of
endothelial cell-matrix adhesion.
The role of CD151 in endothelial cell-matrix adhesion, which is consistent with
early observations made from other cell types and from the skin and kidney abnormalities
caused by human CD151 mutant,74,79,127 helps explain the contributions of CD151 to the
endothelial stability of newly formed vessels in angiogenesis. Because endothelial
cell-matrix adhesion becomes diminished in the absence of CD151, endothelial cells are
likely to be relatively easier to detach from the underlying matrix due to 1) the constant
tension from tubulogenesis and branching morphogenesis and 2) shear stress from blood
influx, resulting in the disruption of vasculature. Because CD151 strengthens cell
adhesion mediated by integrin α6β1 and potentiates the ligand-binding activity of integrin
α3β1 by stabilizing the activated conformation of this integrin,83,91 we activated β1
integrins210 and rescued the unstable endothelial network structure formed by CD151 KD
cells (Figure 3-7), supporting the idea that CD151-dependent vascular stability is at least
partially based on its regulation on integrin-mediated cell-matrix adhesion and also
suggesting that CD151 is required for the full activation of β1 integrins. Despite of being
able to fully rescue the defect in endothelial network maintenance caused by CD151
silencing, the activation of β1 integrins cannot stabilize the network structure of
CD151-silenced group to the level of MOCK, suggesting that CD151 is needed not only
for the optimal function of β1 integrins but also for other endothelial cellular events
required for stabilization of vascular structure in a β1 integrin-independent manner.

6.3.3 CD151 Reinforces Endothelial Cell-cell Adhesion
Endothelial cell-cell adhesion is critical for blood vessel formation and stability.
Molecules responsible for endothelial cell-cell adhesion can be classified into two major
groups: Ca2+-dependent cadherins such as VE-cadherin and Ca2+-independent Ig
superfamily proteins such as PECAM-1/CD31. VE-cadherin physically and functionally
associates with catenins and form adherens junctions.10-12 VE-cadherin is essential for the
morphogenesis of vessel-like structure in vitro as well as vascular morphogenesis in
vivo.12-14 Interestingly, integrin α3β1 in epithelial cells modulates epithelial cell-cell
adhesion and the adhesion-associated cytoskeletal organization possibly through its
interaction with E-cadherin junctional complex. Integrin α3β1 coordinates the signaling
from E-cadherin-β-catenin complex and other pathways such as TGFβ1/Smad pathway
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and is therefore important for establishing and maintaining epithelial adherens
junctions.211,212 CD151, in association with integrin α3β1, was reported to promote
epithelial cell-cell adhesion.85,116 The role of integrin α3β1-CD151 complex in
endothelial cell-cell adhesion remains unknown.
Because diminished endothelial cell-cell adhesion could lead to the instability of
newly formed vasculature, CD151 may sustain neovascularization by reinforcing cell-cell
interactions. Indeed, we found CD151 promotes Ca2+-dependent endothelial cell-cell
adhesiveness through stabilizing endothelial adherens junctions and subsequently
maintains vascular stability and barrier function (Figures 4-1 and 4-2).
Next, we defined the signaling mechanism by which CD151 stabilizes endothelial
adherens junctions. In epithelium, integrin α3β1-CD151 complex physically associates
with E-cadherin junctional complex and stabilizes it.116 In endothelium, we demonstrated
CD151 is not required for assembly of the junctional complex consisting of VE-cadherin
and catenins (Figure 4-4). In contrast, we found that CD151 is likely to be essential for
the anchorage of actin filaments from the sub-cortical cytoskeleton meshwork to
VE-cadherin junctional complexes at cell-cell contact sites (Figure 4-5), thereby
modulating the structural soundness of cell-cell contacts.
In addition, based on the observations from cell aggregation assay, we found that
the reduction or loss of CD151 expression also altered Ca2+-independent cell-cell
contacts (Figure 4-1), suggesting that CD151 is also of importance in the functions of
other types of cell-cell adhesive molecules such as PECAM-1 and ICAM-2 in
vasculature. Previous studies revealed that CD151 regulates the heterotypic cell
interactions between leukocyte and endothelial cell in an ICAM-1- and
VCAM-1-dependent manner.118 CD151 facilitates ICAM-1 and VCAM-1 functions
through compartmentalization of these molecules in endothelial cells.118 Of note,
ICAM-1 and VCAM-1 associates with ERM proteins and form transmembrane complex
to anchor cortical cytoskeleton, similar to CD44-mediated cell-matrix adhesion.159-162
Thus, we predict that CD151 is involved in modulating PECAM-1-mediated homophilic
adhesion between endothelial cells by reorganizing membrane microdomains and
reinforcing membrane-cytoskeleton connection.

6.3.4 CD151 Modulates RhoA Signaling-mediated Endothelial Cytoskeletal Tension
The activation of RhoA-Rho kinase-MLC signaling axis induces stress fiber
formation and cytoskeletal tension (Figure 5-1).17 Previous studies have demonstrated
that RhoA signaling-mediated cytoskeletal reorganization is crucial for the maintenance
of endothelial stability.19-21 Excessive RhoA activity disrupts the integrity of blood
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vessels in angiogenesis and selectively induces the regression of vasculatures, whereas
the suppression on RhoA signaling promotes angiogenesis and vessel stability.19-21 In
murine keratinocytes, integrin α3 deletion was found to result in the increase in stress
fiber formation.213 Moreover, CD151 has also been implicated to regulate RhoA activity
in epidermal carcinoma cells.117 In endothelial cells, CD151 effects RhoA signaling as it
does in epithelial counterpart. Loss of CD151 results in excessive activation of
RhoA-Rho kinase-myosin signaling and robust formation of stress fibers (Figures 5-2 and
5-3), leading to the elevated traction of cellular actin cytoskeleton. Our observation from
CD151-silencing endothelial cells supports the idea that CD151 stabilizes newly formed
blood vessels through suppressing RhoA signaling and stress fiber formation. Hence, due
to constantly high intracellular tension, CD151-ablated or -silenced vasculature may
undergo regression in an accelerated fashion with minimal effect on initial formation,
thereby leading to the disruption of capillary structures. Suppressions of RhoA signaling
axis by specific inhibitors C3 transferase, Y27632 and Blebbistatin in CD151-ablated or
-silenced endothelial cells completely block the collapse of endothelial cable network and
maintain the stability of capillary structures (Figure 5-4). Of note, the inhibitors might
have completely blocked the activities of RhoA signaling pathway, i.e., not only the
excessive portions from the loss of CD151 but also the endogenous activities responsible
for its physiological roles. Such inhibitions helped the endothelial cells to better sustain
the capillary structures, further supporting that RhoA signaling promotes the regression of
vasculatures. Together, these findings indicate that CD151 promotes vascular stability in
a manner dependent on RhoA-mediated cytoskeletal tension.
Several observations have implicated that tetraspanins are important regulators of
small GTPase RhoA.117,214,215 However, the signaling cascade linking tetraspanins to
RhoA is still unclear. As shown in the diagram in Figure 5-1, many signal molecules,
such as p115 RhoGEF, p190RhoGAP and the cAMP-dependent protein kinase A (PKA),
function as direct upstream regulator of RhoA. We analyzed these signal pathways to
reveal the upstream signal of CD151-dependent RhoA regulation.
P115RhoGEF is a RhoA-specific GEF, which catalyzes the exchange of GDP for
GTP in RhoA and thus specifically activates RhoA signaling pathway.203 CD151
silencing does not change the level of active p115RhoGEF (Figure 5-7C), indicating that
CD151 is not required for p115RhoGEF activation. Thus, the upregulation of RhoA
signaling upon CD151 silencing is independent of p115RhoGEF. Because p115RhoGEF is
typically activated by GPCRs when GPCRs bind to their ligands such as hormones and
chemokines,187,188 the reduction in or loss of CD151 expression appears not to fall into
this category. Thus, our observation of the unaltered p115RhoGEF activation upon CD151
silencing is consistent with such a criterion.
Among the regulators specific to RhoA, p190RhoGAP is the most extensively
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studied one. P190RhoGAP terminates GTPase activity of RhoA by hydrolysis of GTP to
GDP. 30 RhoA can be suppressed by p190RhoGAP in an integrin-dependent manner.
Integrin-initiated signaling during cell attachment and spreading activates p190RhoGAP by
inducing the translocation of p190RhoGAP to the plasma membrane and phosphorylation of
p190RhoGAP(Figure 5-1).184-186 A similar signaling mechanism may contribute to
CD151-dependent restraint of RhoA because of the functional overlapping between
CD151 and integrins. However, we found that the diminution or loss of CD151 expression
does not change the p190RhoGAP activation, i.e., neither level of its tyrosine
phosphorylation nor level of the p190RhoGAP proteins that bind to the constitutively
active RhoA (Figure 5-7A and B), indicating that CD151 is not required for p190RhoGAP
activation. This finding also reveals that CD151-mediated restraint of RhoA or CD151
silencing-induced upregulation of RhoA is independent of p190RhoGAP.
CAMP/PKA signaling-mediated phosphorylation provides another type of
regulatory mechanism for RhoA.189,190 Since we observed that elevation of intracellular
cAMP could rescue the unstabilized vascular structures formed by CD151-silenced
endothelial cells in a dose-dependent manner (Figure 5-6A and B), we therefore provide
evidence that cAMP signaling is intimately involved in CD151-dependent vascular
stabilization. Together with the finding that CD151 restrains RhoA activation and the fact
that the protective effect of cAMP on endothelial barrier properties is at least partially
dependent on RhoA196-200, we conclude that cAMP/PKA signaling is very likely the direct
upstream signal of CD151-dependent RhoA restraint. Our findings favor a novel
signaling transduction model (Figure 6-2) in which CD151/integrin complexes-dependent
signaling trigger production of cAMP and the subsequent activation of PKA, which in
turn phosphorylates RhoA and thus suppresses RhoA activity. As described previously,
de-activation of RhoA by PKA might be dependent on the diminshed RhoA association
with Rho kinase and enhanced interaction of RhoA with RhoGDI and translocation of
membrane-localized RhoA to the cytosol.189,190,199 Thus, the phosphorylated RhoA cannot
activate Rho kinase and MLC and induce stress fiber formation. In the absence of
CD151, insufficient cAMP production leads to deficiency in RhoA phosphorylation and
excessive activation of RhoA signaling.

6.3.5 CD151 Might Be an Important Regulator of Cortical Cytoskeletal Organization
Our results imply that CD151 restrains RhoA activation and stress fiber formation
and sustains Rac1 activity (Figure 5-3D). Together with previous observations from
tumor cells and CD151-ablated endothelial cells,112,117,214,215 these findings suggest an
important role of CD151 in Rho small GTPase-mediated cytoskeletal reorganization
during cell-matrix and cell-cell adhesions. In addition, the diminution or loss of CD151
expression significantly weakens the associations of β1 integrins and VE-cadherin with
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Figure 6-2. The signaling of integrin/CD151 complexes in endothelial cells.
CD151 binds to integrins and activates cAMP/PKA signaling, by which CD151 restrains
RhoA signaling and promotes Rac1 signaling. Therefore CD151 suppresses
RhoA-mediated cytoskeletal orgranizations and lowers cytoskeletal tension.
CD151-dependent restraint on RhoA and activation of Rac1, on the other hand, stabilize
cortical actin meshwork and reinforce the connection of the membrane adhesive proteins,
such as VE-cadherin and integrins, to actin filments, causing globally strengthening of
endothelial cell adhesiveness and subsequently leading to vascular stability.
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detergent-insoluble cytoskeleton (Figures 3-6 and 4-5), strongly suggesting that CD151
strengthens the connection of the cell adhesion proteins in the plasma membrane to
cytoskeletal network, possibly via RhoA (Figure 6-2).
Moreover, we found that CD151 silencing reduced the expression of CD44, a
cell-matrix adhesion molecule. Studies from elsewhere indicate that CD151 promotes
endothelial VCAM-1- and ICAM-1-mediated heterotypic cell-cell adhesion.118 Given the
facts that CD44, VCAM-1, and ICAM-1 bind to actin cytoskeleton through ERM
proteins, it is predictable that CD151 indirectly modulates ERM-mediated anchorage of
cytoskeleton to the plasma membrane. Collectively, CD151 likely regulates the
reorganization of cortical actin cytoskeleton, especially the membrane linkage of
cytoskeleton. A logical explanation for the global effect of CD151 on cortical
cytoskeleton organization is that CD151 expression may directly or indirectly (through
RhoA?) alter the biophysical properties of the plasma membrane. As CD151 was shown
to compartmentalize membrane proteins in the plasma membrane,44,63,79,216
CD151-dependent interaction between membrane and cytoskeleton may thus affect the
order, curvature, and fluidity of the plasma membrane.

6.4 CD151 Coordinates Cell Adhesions and Actin Cytoskeletal Tension

6.4.1 CD151 Strengthens Cell-cell and Cell-matrix Adhesions and Regulates the
Crosstalk between Them
Cellular interactions among cells and with the surrounding matrix are
fundamentally important for tissue morphogenesis. The organisms assemble cells and
extracellular matrix into three-dimensional structures to form tissues.179 Therefore it is
believed that the establishments of adhesion structures could be central events for tissue
morphogenesis.179 Also, the maintenance of the established cell adhesion structures is
obviously critical for tissue structural stability. From the structure biology point of view,
desmosomes and hemidesmosomes share very similar architecture.217 Moreover, the
adhesion complexes at cell-cell and cell-matrix contacts consist of the same components
such as vinculin, α-actinin and talin, which are localized at the cytoplasmic face of both
cell-matrix and cell-cell adhesions and directly linked to actin cytoskeleton.218 On the
other hand, cells have also developed a regulatory mechanism through which a single
molecule can be used to control both cell-cell adhesion and cell-matrix adhesion. A
well-known example is β-catenin. This protein has two distinct roles: one as a
constitutient of adherens junctions and another as a signaling transducer in Wnt signaling
pathway which crosstalks with integrin signaling.219,220 It can be envisioned that cell-cell
adhesion and cell-matrix adhesion are coordinated events during and after development.
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CD151 distributes at both basal and lateral cell surfaces where it colocalizes with
cadherins and integrins, the two major adhesion molecules engaging cell-cell and
cell-matrix adhesions, respectively. In CD151-silenced endothelial cells, the connections
of actin cytoskeleton to both cell-cell and cell-matrix adhesion complexes become less
rigorous (Figures 3-6 and 4-5), suggesting that CD151 very likely coordinates cell-cell
and cell-matrix interactions through the reorganization of actin cytoskeleton. CD151
mediates the crosstalk of these two processes probably by regulating the functions of
common components in cell-cell and cell-matrix adhesions such as the cytoskeletal
“crosslinkers” vinculin, α-actinin, and talin in a RhoA-dependent manner. It remains to be
determined in future studies.

6.4.2 CD151 Regulates Cell-cell Adhesion and Cytoskeletal Tension
Cell-cell adhesion and cell contraction are closely interconnected.29 Cadherin and
Rho family GTPase signalings are also mutually regulated.25-28 For example,
RhoA-dependent cytoskeletal tension promotes the disassembly of cell-cell adhesion via
myosin II-mediated actin reorganization.29 Expression of constitutively activated RhoA
disrupts adherens junctions, where the inhibitors of RhoA signaling reinforce cell-cell
adhesions.26 On the other hands, the adherens junctional complex, which consists of
cadherin, β-catenin, and p120ctn, inhibits RhoA signaling.30 Our observations and
previous findings in cancer cells underscore the interplay between cell-cell adhesion and
cell contraction because the Rho kinase inhibitor Y27632 could restore the dislocalized
AJs, caused by loss of CD151, at cell-cell contacts117 and result in fully recovered
Ca2+-dependent cell-cell adhesiveness in CD151-silenced cells (Figure 4-1). Hence,
CD151 is likely involved in the signaling crosstalk between cell contraction/retraction
and cell-cell adhesion via upregulating RhoA activity (Figure 6-2).

6.4.3 CD151 Balances RhoA and Rac1 Signalings
Recent publications reveal apparently conflicting roles of CD151 in regulating
Rac1 activity in different experimental systems. The observations from CD151 knockout
mouse and overexpression cells indicated that CD151 promotes Rac1 activity,74,85
whereas CD151 silencing in carcinoma cells does not alter Rac1 signaling.117 We have
shown that CD151 is needed for maintaining Rac1 activity in endothelial cells. The
diminution or loss of CD151 expression results in attenuated Rac1 activity and elevated
RhoA activity (Figure 5-3), which are in consistence with the antagonism between Rac1
and RhoA signalings as described in the Bar-Sagi pathway.180 Moreover, cAMP signaling
stabilizes vascular structure by either inducing Rac1 activity, inhibiting RhoA activation,
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or both,196-200 and we indeed observed that elevated level of intracellular cAMP rescues
the phenotypes of CD151-silenced endothelial cells (Figure 5-6A and B). These results
provide evidence that cAMP signaling might be the upstream signal of CD151-mediated
restraint on RhoA in a manner dependent or independent on Rac1. However, based on the
observation from Rac1 fast-cycling mutant (Figure 5-6C), we are able to exclude the
possibility that Rac1 may play a role in CD151-dependent restraint of RhoA activity and
maintenance of endothelial stability. Since elevated level of active Rac1 in
CD151-silenced endothelial cells cannot rescue the deficiency in endothelial stability
caused by the loss of CD151, CD151-dependent maintenances of endothelial stability in
vascular morphogenesis and Rac1 activity are likely to be independent with each other.
Most likely, as summarized in Figure 6-2, cAMP/PKA signaling serves as upstream
signal which differentially modulates both RhoA and Rac1 activity.
Moreover, as described previously, increased Rac1 signaling likely results in the
activation and translocation of p190RhoGAP.30 It is also believed that, to strengthen
adherens junctions, Rac1 facilitates the assembly of cadherin-catenin complex probably by
promoting the association of activated p190RhoGAP with the adherens junctions, leading
to the local inactivation of RhoA (Figure 5-1). In contrast, RhoA suppresses
cadherin-mediated adhesive activity by restraining the establishment of sub-cortical actin
cytoskeleton without affecting cadherin-catenin complex (Figure 5-1).25,30 Since
diminution or loss of CD151 expression alters neither protein-protein interactions within
the junctional complex consisting of VE-cadherin and β-catenin nor activation of
p190RhoGAP (Figures 4-4 and 5-7A and B), CD151 reinforces adherens junctions more
likely through confining RhoA but not through activating Rac1. Together, the observations
support the idea that CD151 balances Rac1 and RhoA signalings in a cAMP/PKA
signaling-dependent manner (Figure 6-2).
We next determined whether CD151 regulates Slit2 gene expression. Slit2 is the
ligand of Roundabouts (Robos). Upon binding to Robo, Slit2 inhibits the activities of
small GTPases Rac1 and Cdc42 and plays important roles in axon guidance and smooth
muscle cell migration.205,221 We found that diminution or loss of CD151 expression results
in elevated Slit2 expression level (Figure 5-7D), which exhibits consistency with the
downregulated Rac1 activity in CD151-silenced cells, suggesting that CD151 sustains
Rac1 activity, at least partially, through Slit2-Robo signaling. On the other hand, in the
absence of CD151, a high level of Slit2 expression may suppress the nuclear
accumulation of β-catenin, as demonstrated in lung cancer cells,222 which in turn inhibits
the gene expression driven by β-catenin, e.g., CD44 expression, and eventually renders
cells less adhesive and invasive. In endothelial cells, Slit2 activates an
endothelial-specific Robo, Robo4. It has been reported that Slit2-Robo4 signaling
promotes vascular stability by inhibiting Rac1-mediated cell migration.204 It appears to be
conflicting with our observation that, in the absence of CD151, the upregulation of Slit2
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expression is accompanied by diminished endothelial stability. This discrepancy is
explainable. In the presence of CD151, Slit2-Robo4 signaling-mediated inhibition of
Rac1 promotes vascular stability. However, when CD151 expression is diminished or
lost, the disruptive effects from deficient cell-cell and cell-matrix adhesions and high
cytoskeletal tension likely override the beneficial effect from Slit2-mediated inhibition of
cell migration, eventually leading to vascular instability.

6.5 Summary and Remarks
In the present study, we revealed the mechanisms by which CD151 regulates
vascular morphogenesis and stability. Our results support the notion that CD151 is
needed for proper endothelial stability of blood vessels. CD151 reinforces endothelial
cell-matrix and cell-cell adhesions and alleviates cell intrinsic traction or contractility.
Our findings also revealed a novel paradigm in which CD151 functions as signaling
switch to balance the activities of Rac1 and RhoA probably through regulating the global
connection of the plasma membrane to actin cytoskeleton, leading to the endothelail
stability.
Our present study has highlighted the cellular and molecular mechanisms by
which CD151 regulates vascular stability. However, several critical questions, some of
which we have mentioned above, emerge from the study. For example, how do CD151
regulate cAMP signaling? Why CD151 has a globe regulatory effect on cortical
cytoskeleton anchorage. Do CD151 determine the biophysical state of plasma membrane?
To answer these questions, future studies may focus on the regulations of CD151 in 1)
cAMP activation and/or compartmentalization, 2) functions/associations of common
components in cell-cell and cell-matrix adhesions such as the cytoskeletal “crosslinkers”
vinculin, α-actinin, and talin, and 3) the order, curvature, and fluidity of the plasma
membrane as well as coordination of the physical properties of plasma membrane and
cortical cytoskeletal organization. Moreover, genetically modified animals with dominant
negative mutants of CD151 will be necessary for interpretation of loss-of-CD151-derived
phenotypic changes and for better understanding of roles of CD151 in vivo as functional
compensation by other tetraspanins might exist in CD151-deleted and -silenced models.
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